Design and development of an elastin mimetic stent with therapeutic delivery potential by Martinez, Adam W.
Design and Development of an Elastin Mimetic 
Stent with Therapeutic Delivery Potential
A Dissertation  
Presented to  
The Academic Faculty  
By  
Adam W. Martinez 
In Partial Fulfillment 
Of the Requirements for the Degree 
Doctor of Philosophy in Biomedical Engineering 




Design and Development of an Elastin Mimetic 
Stent with Therapeutic Delivery Potential 

Approved by: 
Elliot Chaikof, M.D.,Ph.D., Advisor 
Dept. of Biomedical Engineering  
Georgia Institute of Technology  
Dept. of Surgery 
Harvard Medical School
Mark Allen, Ph.D. 
Dept. of Electrical and Computer 
Engineering  
Georgia Institute of Technology  
Rudy Gleason, Ph.D.  
Dept. of Biomedical Engineering  
Georgia Institute of Technology  
David Harrison, M.D. 
Dept. of Medicine  
Vanderbilt University 
Mark Prausnitz, Ph.D. 
Dept. of Chemical & Biomolecular 
Engineering   
Georgia Institute of Technology  




I have been blessed to have an abundance of colleagues, family, and friends that 
have assisted me on my path to complete a PhD in biomedical engineering. I would first 
and foremost like to thank my research advisor, Dr. Elliot Chaikof, for his support and 
guidance throughout my time as a graduate student in his lab. I would also like to thank 
Dr. Mark Allen for his support and guidance, especially over the last year. I am also 
appreciative of the insight and input my thesis committee, Dr. Mark Prausnitz, Dr. Rudy 
Gleason, and Dr. David Harrison, has given me over the years. I would also like to 
thank the members of the Chaikof and Allen groups for their advice, assistance, and 
camaraderie. I would especially like to thank Dr. Jeff Caves for being a sounding board 
and a great collaborator and Dr. John Wilson for being someone I could talk to all 
matters lab-related and not. I also want to thank Vivek, John Q, and Julie for being there 
to make the lab a better place. In addition to my labmates, I would especially like to 
thank my BME friends for the fond memories and being there when times were tough.  
Obviously, this journey would not have been possible without the unconditional 
love and support of my family. In particular, I would like to thank Marly who has been a 
source of strength in this entire process and transitioned from a loving girlfriend to a 
dedicated wife. I would like to thank my mom for her reassuring phone calls and faith in 
my abilities, and my dad for being an inspiration of what is possible. I would also like to 
thank my brother who was always there when I needed him. Finally, I would like to 
thank all of my other family members for their assistance on this journey.  
I would also like to acknowledge the National Science Foundation and TI:GER 




ACKNOWLEDGEMENTS …………………………………………………………….. iii 
LIST OF TABLES …………………………………………………………………….... v 
LIST OF FIGURES……………………………………………………………………… vi 
SUMMARY ………………………………………………………………………………  ix 
CHAPTER 1: Introduction……………………………………………………………. 1 
1.1 Motivation and Rationale………………………………………………………….. 1  
1.2 Central Hypothesis and Specific Aims …………………………………………… 1 
1.3 Significance ………………………………………………………………………… 2  
1.4 Background…………………………………………………………………………. 2 
CHAPTER 2: Design and Development of Stents …………………………………. 20 
2.1 Introduction ………………………………………………………………………… 20  
2.2 Materials and Methods ……………………………………………………………. 22  
2.3 Results and Discussion…………………………………………………………… 25 
2.4 Conclusion …………………………………………………………………………. 47  
CHAPTER 3: Fabrication of Protein Based Materials……………………………… 49
3.1 Introduction ………………………………………………………………………… 49 
3.2 Materials and Methods …………………………………………………………… 54 
3.3 Results and Discussion …..………………………………………………………... 63 
3.4 Conclusion ………………………………………………………………………… 81 
CHAPTER 4: Crosslinking, Drug Delivery and Endothelial Potential of the Stent 83 
4.1 Introduction ………………………………………………………………………… 83  
4.2 Materials and Methods …………………………………………………………… 85 
4.3 Results ……………………………………………………………………………… 94 
4.4 Discussion …………………………………………………………………… …… 109 
4.5 Conclusion ………………………………………………………………………….. 123 
CHAPTER 5: In vitro and in vivo Stent Deployment………………………………… 124
5.1 Introduction ……………………………………………….………………………… 124 
5.2 Materials and Methods …………………………………………………………….. 126  
5.3 Results and Discussion ……………………………………………………………. 130  
5.4 Conclusion …………………………………………………………………………. 151  
CHAPTER 6: Conclusion and Future Directions ………………………………… 152
REFERENCES …………………………………………………………………………. 156 


List of Tables 
Table 2.1 Design Considerations      21 
Table 2.2 Stent parameters   30 
Table 2.3 Stent Expansion Studies  33 
Table 2.4. Crimping strategies  47 
Table 3.1 Literature Fabrication Table of Stent and Scaffolds   53 
Table 3.2 The fabrication times for the different modalities are defined in 
terms of initial sunk time and time per stent  65 
Table 3.3  Design Fidelity of Fabrication Processes   70 
Table 3.4 Comparing the advantages and limitations of each approach  78 
Table 4.1 Compiled mechanical parameters of noncrosslinked and 
crosslinked protein films   100 
Table 4.2 Shows the percent extractables of the different crosslinking 
methods and shows the degree of crosslinking group interaction.  101 
Table 4.3 Drug Elution Parameters   105 
Table 5.1 In Vitro Benchmarks    131 




List of Figures 
Figure 2.1. Stent Design Variations  28 
Figure 2.2. Collapse Pressure Setup  37 
Figure 2.3. 6mm Stent Designs with a 200µm thickness (A) Different 
elastin mimetic materials and crosslinking strategies (B) Changing the 
strut widths (C) Stents with and without rings (D) Altering the diameter but 
keeping the same design and thickness 200µm   40 
Figure 2.4. (A) Collapse pressure for stent with different widths, (B) 
collapse pressure for stent designs that have different cell sizes, (C) 
collapse pressure for stent designs without and with rings, and collapse 
pressure of stent design with ring fabricated into stents with different 
diameters.   42 
Figure 2.5. (A) Commercial Crimping Strategies, (B) Mylar sheet crimping 
strategy, (C) advantage of pleating the balloon with regard to radial profile 
(D) die for pleating balloon and stent, (E) Funnel pleating device to pleat 
the balloon, (F) Pleated Balloon, (G) stent on balloon before pleating (H) 
folded Stent (I) wrapped stent   45 
Figure 2.6. Final fabricated crosslinked stent  48 
Figure 3.1. (A) Ablation depth vs. pulse number curve for 10 energy 
levels, (B) SEM micrographs of EM ablated holes with an increase in 
pulses in the x direction and energy in the y-direction   55 
Figure 3.2. Schematic of Excimer Ablation   57 
Figure 3.3. A combinational approach was used to generate stents from 
protein polymer solutions. (A) PDMS mold patterned with the stent design. 
(B) PDMS mold overfilled with elastin mimetic material.  (C) Mask placed 
on top of the webbing from the solvent casting (D) Elastin mimetic in mold 
after the webbing is ablated with an excimer laser. (E) A stent that has 
been unmolded. (F) A rolled and attached stent.   60 
Figure 3.4. PDMS molding was used to generate 3D structures from 
protein polymers. (A)The filling of a PDMS mold with protein polymers 
illustrated webbing perpendicular to surface after one pour, webbing 
perpendicular to surface after three pours, an ideal case with no webbing 
and a filled well, and an overfilled mold with webbing parallel to the 
surface.   71 


Figure 3.5. Samples A-F are 10X optical images (A) after over filled 
molding (B) and (C) after one and three rasterings respectively 
unprotected (D) after three rasterings with mask, (E) unmasked rastering 
three passes and (F) masked rastering after three passes.   74 
Figure 3.6. (A) LysB10 film raster with excimer laser for 3passes 2 passes 
and 1 pass. (B) SDS Page gel of three samples a) LysB10 in water, b) lys 
B10 cast from TFE, c) laser ablated LysB10 (C) % Extractables from laser 
ablated samples and control LysB10.     76 
Figure 3.7.  (A) Planar Stent Sheet (B) Picture of planar and rolled stent 
(C) End profile of stent overlapping (D) End profile of stent  abutment 
attachment  79 
Figure 4.1.  Confined crosslinking setup  87 
Figure 4.2.  (A) Thickness ratio of the different crosslinked samples, (B) 
Water content of the various crosslinked films, and (C) The swelling ratio 
of the different crosslinked samples. The unconfined samples are shown 
in black the confined are light gray and the vapor are dark gray.   96 
Figure 4.3. Stress strain plots for (A) control constructs, (B) genipin 
crosslinked constructs, (C) glutaraldehyde crosslinked constructs, and (D) 
thiol crosslinked crosslinks.  99  
Figure4.4 (A) Illustrates the elution profile of LysB10 and three types of 
drug distribution. (B) depicts the difference between different genipin 
crosslinking conditions, (C) shows affect of different GTA crosslinking 
methods, and (D) Shows the difference between thiol crosslinking 
methods   104 
Figure 4.5. Optical images of LysB10 solvent cast films seeded with cells 
at 2 and 48 hours. Images A and B are for Lys B10 with no Fn adsorbed at 
2 and 48 hours respectively. Images C and D are for Lys B10 with Fn 
adsorbed at 2 and 48 hours respectively.  Images E and F are for Lys B10 
with Fn adsorbed after a genipin crosslinking step at 2 and 48 hours 
respectively. Images G and H are for Lys B10 with Fn adsorbed after a 
glutaraldehyde crosslinking step at 2 and 48 hours respectively. Images I 
and J are for Fn adsorption onto thiol modified Lys B10 crosslinked via 
disulfides crosslinking step at 2 and 48 hours respectively. Images K and 
L are for Fn adsorbed non tissue culture PS at 2 and 48 hours respectively  108 
Figure 4.6 (A) Shows the cell adhesion on the different crosslinked 
surfaces with Fn adsorbed. In this panel all cell numbers have been 
normalized to the Fn surface. (B) Shows the adhesion and proliferation on 
the different crosslinked surfaces.  109 


Figure 5.1 (A) Standard catheter design, (B) Experimental catheter 
design, (C) Zoomed in portion of B, a denoted balloon, b denotes attach 
mend point, c is inner lumen, d is outer lumen and (D) The distal end of 
the catheter   132 
Figure  5.2 (A and B) Uncrimped Stent (C and D) Crimped Stent   137 
Figure 5.3 Collapse Pressure Before and After Stent Loading   141 
Figure 5.4  (A) Stent rings with different concentrations of tantalum(B) 
Stent rings examine through fluoroscopy with commercial stents above 
and below (C) EWlastin mimetic stent doped with tantalum inside the 
delivery catheter (D) Stent half way out of the delivery catheter.   143
Figure 5.5. (A) Illustrates the potential for crosslinking to extend elution 
profiles. (B) Illustrates the elution profile for a crosslinked elastin based 
stent that has the drug located in discrete portions of the stent.   145 
Figure 5.6. (A) Cell adhesion and proliferation on Fn polystyrene and Fn 
on stent section. (B) Genipin crosslinked stent after 2 and (C)48 hours 
post seeding.    148 
Figure 5.7 Diagram of rat circulatory system 
(http://www.biologycorner.com) (B) Site of Deployment (C) exposed 
ligated aorta, and (D) catheter loaded into the aorta   150 





Stenting remains a common treatment option for atherosclerotic arteries. A stent 
is a thin walled tube with fenestrations capable of being delivered to and expanded in a 
section of a vessel that has been narrowed or blocked with atherosclerotic plaque to 
open and maintain the patency of the vessel. The main drawback of early stent 
platforms was restenosis which has been combated by drug eluting stents (DESs). The 
current limitation facing these DESs is late stage thrombosis. The major research 
focuses in this field has been the development of the next generation of DESs and first 
generation bioabsorbable stents to combat current stenting limitations.  
The main objective of this proposed research was the design and development of 
a new class of bioabsorbable stents composed of elastin mimetic protein polymers. The 
initial work focused on the ability to process these protein polymers into stents and 
ensure they possess the necessary mechanical strength to serve as stents. Once that 
endpoint was achieved optimization of both the stent design and fabrication process 
were explored. Preliminary investigations have demonstrated the ability of elastin 
mimetic materials to have the mechanical integrity to serve as a material for stent 
development. These materials have been fabricated into stents through the use of 
molding and laser ablation. The drug loading capacity of these elastin mimetics were 
explored to allow for the inhibition of restenosis. The ability of the elastin mimetics to 
recruit and promote the endothelialization of the stent lumen was also explored. Finally, 
the capacity of these elastin mimetics to overcome the current limitations of current 





1.1 Motivation and Rationale  
Stenting is a billion dollar industry that is still limited by restenosis and late stage 
thrombosis(LST). The development and acceptance of drug eluting stents(DESs) has 
allowed for dramatic reductions in restenosis. However, DESs have led to a rise in LST 
caused by a reduction and delay of endothelial coverage.  We believe that our protein 
polymer technology will allow us to overcome the limitations of current stent platforms 
through the implementation of advanced bioabsorbable thromboresistant materials and 
sustained local delivery of therapeutics.  
1.2 Central Hypothesis and Specific Aims 
The central hypothesis encompassing this dissertation is that recombinant elastin 
mimetic proteins can be used to create stents that provide a scaffold for remodeling of 
the vascular wall after angioplasty while inhibiting restenosis and thrombosis formation 
by local delivery of anti-restenotic agents and facilitating accelerated endothelialization. 
The overall objectives of the work detailed in this dissertation were i) the fabrication of a 
vascular stent from an elastin mimetic protein polymer with targeted mechanical 
properties, conformability, and deformability, ii) devise general fabrication strategies for 
the fabrication of fenestrations in protein polymer films, iii) tailor the recombinant elastin 
mimetics to allow for delayed drug delivery and endothelialization, and iv) combine this 
knowledge to implant a stent in vivo. 
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1.3 Significance and Scientific Contribution  
The clinical efficacy of endovascular therapy, including stent placement, remains 
limited by restenosis and thrombosis. The proposed research is significant because it 
represents a unique approach for improving stent performance with the establishment of 
a new paradigm in medical device development in which a device is constructed from a 
non-thrombogenic structural protein that contains therapeutic agents. In the 
development of this device, we have developed fabrication strategies that are being 
used by collaborators to fabricate constructs from biological tissue. We have also 
developed crosslinking techniques that can enhance protein polymer performance 
without reengineering the sequence.   
1.4 Background   
Vascular stenting is a common procedure used to treat atherosclerotic vessels.  
Cardiovascular disease continues to be the leading cause of death in the US and 
the rest of the western world. In the US, cardiovascular disease accounts for one in 
three deaths. One of the most pressing areas in cardiovascular disease is the narrowing 
and occlusion of vessels with atherosclerotic plaque, which limits and ultimately 
prevents blood flow to the heart and other organs.  Vessels with severe atherosclerotic 
plaque can be treated with an open procedure where the vessel with the plaque is 
replaced or a minimally invasive procedure where the vessel is opened from the inside. 
Over the past twenty years, vascular stenting has become the most common minimally 
invasive procedure for treating atherosclerotic plaque because of its capacity to reduce 
recovery times and decrease surgical expense. The procedure alleviates the blockage 
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in a vessel by cracking the plaque with an angioplasty balloon. Then an angioplasty 
balloon with a mounted stent is inserted and guided to the site of the previous blockage, 
and the stent and balloon are expanded to completely reopen the vessel. The balloon 
and catheter are removed leaving the stent behind to provide a scaffolding to keep the 
vessel patent as the vessel remodels.  Stents have shown promise as a successful 
minimally invasive approach to treating atherosclerosis.  However, the increased usage 
of stents has highlighted the serious shortcomings of the currently approved stent 
designs and platforms.   
Stents are currently plagued by two major complications.  
Stent restenosis and thrombosis are the major causes of stent failure today. 
Restenosis is the formation of new blockages at the site of angioplasty or stent 
placement, resulting from tissue growth at the site of treatment caused by an over 
proliferation of the smooth muscle cells (SMCs). Restenosis tends to occur during the 
first 3 to 6 months after the procedure, and the incidence rate has been decreased by 
the development of drug eluting stents (DESs). DESs seem to provide a solution to one 
of the problems that affected stents, but in so doing have created another, as they lead 
to an increased rate of thrombosis, especially LST. The risk of thrombosis is the 
greatest immediately after angioplasty because the resultant tissue trauma tends to 
trigger blood clotting; however, this type of thrombosis formation has been greatly 
reduced by using antiplatelet drugs during and after the procedure. However, LST is 
more complicated to treat as it can occur at unpredictable time points despite the use of 
antiplatelet therapy as illustrated in a 3 year follow up study [1]. Future stent designs 
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must minimize the risk of these complications through careful consideration of stent 
design and deployment. 
Approved and Developing Stent Platforms  
Extensive clinical trials have examined the viability of different stent designs, 
material choices, and coatings. In the field of stenting, there have been incremental 
improvements to stents.  Bare Metal Stents (BMSs) were initially used in the treatment 
of atherosclerosis. The next improvement was the addition of a therapeutic in the form 
of DESs. The next frontier appears to be bioabsorbable stents which have the potential 
to revolutionize the stent field and are currently under development in both industrial 
and academic settings. Bioabsorbable stents have the potential to perform their function 
and then absorb into the vessel leaving behind no permanent foreign body. There are 
currently several bioabsorbable stents in the development stages for different 
companies. In addition to bioabsorbable stent platforms, significant research 
expenditures from both commercial and academic researchers are focusing on 
advanced coatings for approved platforms to decrease platelet formation and enhance 
drug delivery and endothelialization. Researchers are attempting to achieve these ends 
via extremely varied thin coatings on proven platforms, discussed in the following 
sections. The following three sections will discuss the emerging technology in the three 
specific areas: stent platform, drug release, and endothelialization.  
Stent Platforms Currently Used and Under Investigation 
The most important choice in stent design is the material selection. The material 
selection is critical because this decision dictates stent design and function. Most of 
today’s stents are made from 316L stainless steel, nitinol, or cobalt chromium. These 
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metals have been carefully chosen over the years for their mechanical properties. In the 
mid 90’s, there was an unsuccessful push for polymer stents. There were several 
reasons for the demise of this idea, such as, thrombogenicity and improper degradation 
kinetics. Today polymeric stent research has been revived because of new polymers 
and their versatility in manufacturing, drug delivery and degradation. Since we are 
mainly focused on the polymer side, the literature will focus on the progress in that field. 
However, I will discuss some of the leading principles behind the highly successful 
metallic stents. 
The suitability of a new material must be considered on several fronts such as 
machinability, mechanical properties, and biocompatibility. Elastic materials can provide 
a challenge as they have a large amount of recoil. This is why some polymeric stents 
depend on elastic recoil or ratcheting mechanisms to keep them open. However, when 
designed properly the recoil can be eliminated, and elastic materials have the ability to 
return to their deployed form after a crushing injury which prevents permanent collapse. 
Drug Eluting Stents (DES) and current work to address their shortcomings 
DESs typically consist of a BMS, a therapeutic, and a polymeric drug delivery 
system.  Drug eluting stents have shown great potential in preventing restenosis; 
however, they come with side effects discussed above.  These side effects have been 
linked to both the drug and the coating aspects of DESs. This has led researchers to 
look at new coating options and explore different types of therapeutics.  
To overcome the polymer coating issues, researchers have experimented with various 
families of biocompatible polymers as well as polymer free stents. These polymer free 
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stents have been able to circumvent the need for polymer delivery systems by 
incorporating drug releasing reservoirs into stents, fabricating porous surfaces, and 
applying novel coating strategies to existing stent platforms. An example of a stent that 
contains a microporous coating include the Corel-C™ stent  that is fabricated from CoCr 
with a carbon nanoparticle coating (Relysis Medical, India) [2].  Microporous surfaces 
have also been incorporated into polymer based bioabsorbable stents [3].  As noted, 
sandblasting has been used to create pores between 1 to 100 µm on the surface of 
stainless steel stents, an example of which is the Yukon™ stent platform(Translumina, 
Hechingen, Germany) [4].  Adsorption of rapamycin along with other drugs has proven 
feasible and showed a dose-dependent efficacy in prevention of restenosis [5]. 
However, the rapamycin eluting Yukon™ stent was found to be clinically inferior to the 
Cypher™ stent, as well as a version of the Yukon™ stent coated in a drug containing 
bioabsorbable polymer [6]. At least two examples exist of nanoporous stent surfaces. 
The Jomed™ coating consists of a thin aluminum base layer, which is then subjected to 
an acidic solution that converts the aluminum into a thin ceramic nanoporous aluminum 
oxide[7]. A recent report suggests that particle debris may be released from the stent 
surface [8]. MIV Therapeutics, Inc. has developed a stent with a hydroxyapatite coating 
that is 0.30 to 1m in thickness with a porosity of 40-60% in volume [9]. This stent has 
shown promising responses in both animal studies and in an initial clinical study after 
adsorption of sirolimus[10]. The therapeutics that DESs release has also been 
extensively researched. The majority of the early therapeutics used were 
antiproliferative drugs such as sirolimus and paclitaxel. Recently novel therapeutics 
have been introduced to target specific cells of interest.  
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Biopharmaceuticals have also seen great use in the academic arena as a more 
tunable system that could speed vascular wall remodelling. Peptides [11], DNA [12], 
and heparin [13], as well as anti-platelet agents, such as abciximab [14], growth factors 
and integrin binding sequences have been incorporated onto stents to reduce 
thrombosis or increase endothelial migration. An enzymatic release system for releasing 
RGD as the therapeutic from a stent surface was also researched. RGD was shown to 
be eluted in an enzyme concentration dependent manner by an exogenous enzyme 
given systemically. The researchers have identified other peptides that adsorb strongly 
to an array of stent materials which allows for beneficial uniform application and active 
delivery of a large range of peptides[15]. RGD-containing peptides have also been 
shown to be effective inhibitors of platelet aggregation and smooth muscle cell 
migration, by the prevention of certain ligand binding activities leading to a reduction in 
neointima formation[16].
Enhancing Endothelialization 
The improvement of stent lumen endothelialization has been looked at on two 
main fronts: increasing endothelial cell migration and recruitment of circulating 
endothelial cells. To this end researchers have focused on the physical and chemical 
properties of a stent’s surface and the integration of biopharmaceuticals on to stent 
surfaces.  
Topologically rough surfaces have been created via microblasting and reactive 
ion etching leading to improved cell attachment [17]. Nanoscale surface features 
produced by polishing have influenced endothelial cell proliferation and protein 
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expression.  Patterned Ti with grooves ranging from 750nm to 200m have also shown 
enhanced endothelial coverage on nanometer scale patterns compared to micron scale 
patterns or random nanostructured surfaces[18].   Nanometer patterns can also be 
produced in a manner that leads to endothelial cell alignment that mimics native 
endothelium[19]. Of note, surfaces with a defined nanopatterned grid demonstrated a 
greater degree of endothelial cell adhesion, as compared to responses observed on 
random nanostructured surfaces[20]. Nanostructured surfaces, when compared to 
microstrutured surfaces, appear to afford greater adhesion of endothelial cells than 
smooth cells [21], lead to higher cell densities [22], and enhanced adhesion and 
spreading[23]. Interestingly, features between 100nm and 1µm have yielded greater cell 
adhesion densities than those less than 100nm[24]. The molecular mechanisms of 
these effects have not been well defined, but may be related, in part, to changes in 
protein adsorption profiles. 
Surface modifications that alter surface chemistry can influence protein and cell 
adhesion leading to enhanced endothelial cell growth and proliferation[25, 26].   Recent 
examples include sputtering TiO2 onto 316L stainless steel [27] and binding tropoelastin 
to plasma treated metal surfaces, which enhanced cell attachment and proliferation [28]. 
Also cold plasma grafting of polypeptides that mimic mussel adhesive have imparted 
improved EC adhesion and accelerated growth, while maintaining favorable blood 
contacting properties[29]. 
In the biopharmaceutical space researchers have looked at enhancing 
enothelialization through the delivery and adsorption of both plasmids coding for 
vascular endothelial growth factor (VEGF) [30] and VEGF [31]. Cyclic Arg-Gly-Asp 
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(cRGD), as well as  anti-CD34 and anti-kinase insert domain antibodies have been 
applied to increase the recruitment and retention of endothelial progenitor cells[11] and 
have shown initial success [32]; however, the latest research has shown some 
concerns[33]. 
Elastin mimetic protein polymers have been known to possess advantageous 
blood contacting properties, tailorable mechanical properties, and drug delivery 
potential which makes them an ideal stent material.
Genetic engineering has provided researchers a method to design and 
synthesize a wide variety of polypeptides. These polypeptides are able to have 
precisely controlled molecular architectures, amino acid sequence, and size that can be 
easily manipulated by altering the sequence and length of the encoding DNA. A 
common family of recombinant polypeptides is elastin analogs that are derived from the 
native elastin repeat found in human elastin. A large portion of our lab’s focus has 
revolved around the design and development of several classes of elastin mimetic 
analogs. These have been built on the foundation of synthesizing elastin mimetic 
analogs with additional amino acid residues and/or certain cell recognition sequences. 
These large multiblock protein polymers offer a unique opportunity to systematically 
modify material microstructure to generate materials with a wide array of mechanical 
properties, drug delivery potential, and advanced surface properties. While these 
complex material compositions have been looked at in some detail for other 
applications, this is the first time they have been used in the development of a stand 
alone protein device. This foray into stent development is logically based on the 
scientific benchmarks that this material has cleared. These benchmarks include the 
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ability of these material to have mechanical properties that can be tailored to provide a 
wide range of elastic moduli, the ability to encapsulate drugs, advanced blood 
contacting properties, and the ability to enhance endothelialization.  
Tailorable Mechanical Properties 
The mechanical and biological properties of elastin mimetic proteins can be 
modulated by different processing solvents, protein concentrations, crosslinkers, and 
the addition and deletion of certain amino acid residues. While the basic processing 
conditions have been well documented, there is a lack of data on the processing 
techniques and fabrication modalities capable of being used. Therefore, all fabrication 
techniques used in the development of medical devices from elastin mimetics have the 
potential to unsuspectingly change the physical and biological attributes of these 
materials. The ability to tailor the mechanical properties and degree of swelling of 
elastin like protein gels and films has been shown with changes in protein 
concentration, crosslinker concentration, lysine content, and molecular weight[34-38]. 
Some of the crosslinking agents used were tris-succinimidyl aminotriacetate [34], 
glutaraldehyde [35], hexamethylene diisocyanate [36], bissulfosuccinimidyl suberate 
[37], and disuccinimidyl suberate [37]. On a more specific, note hexamethylene 
diisocyanate crosslinking provided a higher elastic moduli than glutaraldehyde [36], and 
a mechanical difference was noted when two different crosslinking strategies, a 
crosslinked solution and a solvent cast film setup, were used [37]. In our lab it has been 
shown that our elastin mimetic materials can have their properties tailored with judicious 
selection of both solvents and processing conditions as these control the meso- and 
nanoscale structure of the proteins [38]. 
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Drug Release Potential 
Drug release from elastin like materials and other protein coatings has been 
utilized in the stenting field, but more thoroughly in the tissue engineering space. 
Previously, gelatinous [39, 40] and collagenous [41, 42]materials have been used to 
create therapeutic eluting protein stent coatings. Of specific note was the ability to 
control sirolimus release via a topcoat of genipin crosslinked collagen [41]. Also of note 
is the development of a stent coating created from a thin collagenous tissue inoculated 
with EPCs that were able to migrate and proliferate forming a completely 
endothelialized lumen in vitro [42]. Elastin like proteins, similar to the ones used in this 
proposal, were capable encapsulating and delivering drugs in solution form [43] and in 
the form of micro- and nano-particles [44].  
Valuable Blood Contacting Properties and Endothelialization Potential 
Elastin is considered to have advantageous blood contacting properties due to 
the fact that elastin is a structural protein found in native vessels and induces minimal 
amounts of platelet adhesion and aggregation [45]. Researchers in our lab have also 
shown that a recombinant elastin mimetic protein polymer coated on 4mm grafts in an 
acute primate ex vivo shunt model induces minimal thrombogenicity [46]. Other 
researchers have also found that recombinant elastin polypeptides passively adsorbed 
onto synthetic surfaces can decrease platelet deposition and activation in vitro [47]. 
Additionally increases in the degree of crosslinking via genipin have shown the ability to 
increase the hemocompatibility of some proteins [41]. 
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Elastin mimetics can be altered to allow for an enhanced rate of 
endothelialization capable of preventing LST and recapitulating the native lumen 
environment preventing further stenting complications. Incorporation of cell binding 
sequences and/or biopharmaceuticals have allowed for enhanced endothelialization 
through the recruitment and adhesion of endothelial cells. As alluded to earlier, the fact 
that elastin mimetic materials are made through recombinant means allows researchers 
to splice cell binding motifs into the native elastin repeat sequences. The addition of cell 
binding sequences allows for tailored cell responses based on the cell binding 
sequences chosen. Researchers constructed elastin like proteins with fibronectin CS5 
domains [37, 48, 49] of note was the ability of HUVECs to adhere and remain on this 
modified elastin surface after being subjected to physiologically relevant stresses [49]. 
The addition of an RGD sequence to a specific protein has been shown to be superior 
in terms of binding endothelial cells more strongly and inducing faster cell spreading 
than a CS5 cell binding sequence[50]. Elastin like proteins with RGD present in the 
structure were capable of being coated on different materials with complex geometries 
via adsorption and imparted enhanced surface properties for cells to these materials 
[51]. Increasing the density of RGD domains in crosslinked films showed the ability to 
modulate cell adhesion and spreading [52]. The crosslinking of these films via lysine 
residues, which is required for the mechanical properties we need, can affect the cell 
binding sequences.  Lysine residues were shown to have an affect on the efficacy of 
cell binding sequences when placed within or near the binding sequence; however, 
lysine residues on the end of the protein sequence do not affect the degree to which 
HUVECS were able to adhere and spread[53]. It has also been shown that altering a 
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cell binding sequences can prevent HUVEC spreading [54]. These studies show that 
the addition of RGD can provide a surface capable of enhanced endothelialization, but 
steps in the fabrication process could ultimately have a significant impact on HUVEC 
spreading and adhesion by altering the conformation of the protein or the binding site. 
While elastin can be tailored to increase endothelialization, it should be noted that 
elastin coatings have also been reported to inhibit smooth muscle cell migration without 
affecting endothelial cell migration[55]. 
Mechanical Thresholds 
The mechanical properties of commercially available stents have been tested 
using several methods with the most widely accepted test being the collapse pressure 
test. This setup will allow us to determine the mechanical potential of new stent designs 
and material composition. While it would be beneficial to create a formula that could be 
predictive of the mechanical strength without having to make and test the stent, this is a 
near impossible goal given the ever changing mechanical properties of the elastin 
mimetic material. There are some groups that have created finite element analyses of 
stents, based on commercially available stents and assumptions on things such as 
vessel properties[56-58]. However, the challenge with our work is the material 
properties are not standard, which creates an enormous hurdle when devising an 
analysis. Therefore, we have chosen to ascertain the collapse pressure of our material 
in several designs and analyze the trends. The number one hurdle was ensuring our 
stent design has a sufficient collapse pressure. This leads to the question what is the 
minimum value of collapse pressure needed? Agrawal et al. came up with a minimum 
acceptable collapse pressure of 300mmHg. This was ascertained by assuming that the 
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average intraluminal pressures in an artery to be stented were on the order of 100 
mmHg. If this is assumed and a stent is designed to withstand the difference between 
the transluminal and intraluminal pressures or pressures up to 175 mmHg, and a factor 
of safety is added then a calculated minimum acceptable collapse pressure for stents is 
300 mmHg or 40 kPa [59]. 
Discussed below are some of the collapse pressure trends found in the literature. 
Although most of the data is on older stent designs and SS and nitnol stents, the trends 
are valuable for both the differences in stent design and material choice. PLLA stents 
with diameters ranging from 1.6 to 2.4 mm were fully expanded to 2.3–4.7 mm and were 
shown to have a collapse pressures ranging from 40-240 kPa, depending on the 
thickness and other design parameters [60]. The collapse pressure of PLLA stents has 
been shown to be in excess of 40kPa [61] and in the case of the Duke stent, 100 kPa. 
In another study on PLLA stents, researchers discovered that collapse pressures were 
molecular weight dependent, with a range of 180-250 kPa, and design dependent, 
helical stents have a collapse pressure 100kPa lower then their tubular counterparts, 
and the addition of drugs, especially at higher amounts, decreased the collapse 
pressure of the stents [62]. A look at 3mm SS stents showed a collapse pressures 
ranging from 65.86 - 71.94 kPa with a high outlier of 106.39 kPa; after these stents 
reached their collapse pressure they collapsed abruptly [63]. Other tests revealed that 
most nitinol stents with a diameter of 3.5mm had a collapse pressure ranging from 53-
80kPa. It also showed that stents without struts in the longitudinal direction connecting 
radial segments had lower collapse pressures [64].  A study of peripheral stents, with a 
diameter of 8mm and a length of 37-40mm, showed self expanding stents had collapse 
15 

pressures around 20kPa and balloon expandable stents had collapse pressures around 
90kpa [65].  
A process needed to be determined to allow us to calculate the collapse pressure 
for future designs based on the experimental results of previous designs. There are 
some basic equations that allow us to elucidate the most important strength factors for 
stent viability before the fabrication process.  In looking at the collapse pressure and the 
necessary radial forces there seem to be two main things that need to be focused on. 
The first is when does a stent fail which is different for balloon expandable and shape 
memory stents. When balloon expandable stents collapse they do not return to their 
previous shape where as shape memory stents return to their initial starting diameter. In 
the elastin mimetic stents shape recovery occurs so they can be considered with the 
shape memory stents. The other point necessary is when does ovalization begin 
because once this happens the extra force applied rapidly collapses the stents. The 
term ovalize is simply the process of an object losing round. Even in the commercially 
available stents this ovalization usually occurs because the forces while uniform never 
exert the necessary axi-symmetric forces needed to cause the stent to close its cells. 
Elastic ovalization was described by Timoshenko and Geere for thin walled shells which 
are similar to the stents we are researching. They derived an elastic ovalization 
pressure equation that can be found in support documents. Thin wall tubes, however, 
become harder to calculate if slots are placed in them. Also in commercially available 
stents the open area increases as the stent is expanded. However, in our testing the 
slotted area versus the material area is known based on the design used. This 
ovalization point is also critical during stent fabrication and deployment because the 
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degree to which the stent is out of round can have a large impact on its ability to support 
extra weight.  
Determine Drug Delivery Thresholds, Release Profiles and Delivery Modes. 
Currently there is not an optimal drug or release profile for DESs. This is a result 
of several confounding factors ranging from limited release of proprietary data, failures 
of current designs, variations in current release technology, and an ever evolving 
knowledge of drug kinetics in the vessel. In FDA disclosures stent companies have 
focused more on the safety of drug levels then the efficacy of different drug levels. 
Therefore, there are a multitude of variables that need to be studied to determine what 
drug, release profile, and mode of delivery should be selected. Given the release matrix 
will be elastin the things to focus on are the drug choice, existing release profile, 
alterations to release profile, and mode of release.  
The choice of drug is important as researchers have shown differences in drug 
distribution between hydrophobic and hydrophilic drugs. In the vasculature, hydrophobic 
drugs get deposited more heavily in the intima and adventia [66]. Drug uptake is also 
influenced by the organizational and variable avidity of drug uptake in different arterial 
components [67]. Drugs such as rapamycin and paclitaxel are both hydrophobic but 
have different uptakes and interact differently within arterial structures. Therefore one 
must look at both the physical and chemical attributes of a drug to determine which to 
use in a given application [68]. Stent based drug delivery can be misleading as the local 
concentration is linked to biological effect, but the proximity of the stent does not ensure 
needed local concentrations because physiological transport forces cause local 
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concentrations to deviate significantly from mean concentrations [69]. This is reinforced 
by the fact that drug deposition in the vessel is dominated by flow mediated deposition 
of blood solubilized drug instead of abluminal coating contact with the vessel [70]. The 
two most common choices for DESs are rapamycin(sirolimus) and paclitaxel. Research 
has suggested that LST occurred more frequently with paclitaxel stents compared to 
sirolimus[1].  These two drugs differ significantly in terms of their effects on cells and 
ability to prevent restenosis [68, 71-75]. The needed dose and duration of the drug are 
also drug dependent. In order to prevent smooth muscle cell over proliferation the drug 
should be kept around the minimum effective concentration for one month. 
The release rate is primarily controlled by the drug and the matrix the drug is 
encapsulated within and as such by changing the matrix material and drug combination 
the duration of delivery can be altered.  An ideal release rate will allow for a drug 
concentration in the local tissue with a concentration necessary to overcome restenosis. 
The ability of drugs to diffuse through a polymer coating is also polymer and drug 
specific as different drugs can diffuse through a common matrix material at different 
rates. Using paclitaxel as a model, drug in vitro release was shown to be dependent on 
the initial weight percent of the drug [76] and using HPLC in vitro drug release exhibited 
a first-order release profile in which 36% and 55% of the drug was released after day 1 
and day 7 respectively [77]. The sirolimus slow release Cypher stent was found to have 
no significant difference compared to BMS at time points of 90 and 180 days while there 
was a 50% reduction in neointimal area at 30 days [78].  
The bridge between release profile and mode of release resides in the ability of 
stents to deliver drugs for the necessary duration without having the concentration too 
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high in the initial stages. Extended release profiles have been demonstrated from DESs; 
however, the architecture of DESs provide only a thin coating from which to deliver 
drugs, therefore sustained drug delivery is possible but it tends to be at concentrations 
that are not relevant. The total amount of drug a stent can hold is usually dependent on 
the coating thickness. However, since bioabsorbable stents are made from a potential 
drug carrier the only limit will be to maintain the structural integrity of the stents [79].  
Several modes of delivery exist for DESs that are a results of drug choice, matrix 
construction, encapsulation technique, and matrix. The most common method of 
release in commercially available stents is diffusion. Besides diffusion, degradation can 
also allow for drug release or in some cases release can come from both diffusion and 
degradation [80]. Diffusion has been favored as the by products of coating degradation 
have led to negative inflammatory responses. The bioabsorbable stents that have been 
researched have shown the potential to have both diffusion controlled release and 
degradation controlled release as long as the degradation is slow enough to preserve 
the mechanical integrity of the stent for extended time periods. Models have been 
developed to predict PLA degradation and drug release [81]. Coating stents with 
different types of matrices has also been studied. One example is elution of rapamycin 
from the Cypher stent through a permanent polymer, a bioabsorbable polymer and 
polymer free coating. In this case the drug in the polymer free stent was completely 
gone after two weeks and it had inferior efficacy while the bioabsorbable platform was 
as effective as the permanent polymer [82]. Layers of drug and polymers and drug 
reservoirs also allow for flexible and controlled pharmacokinetics profiles [83]. 
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Enhancement of Endothelialization 
The end goal of any stent lumen is to passivate the luminal surface of a stent 
with a quiescent endothelium. This need has been exacerbated by the current DES 
platforms which have lead to an increase in LST as discussed above. DESs have 
delayed endothelialization because the therapeutics they release cause endothelial cell 
death along the entire length of the stent compared to standard BMSs that limited cell 
death to the area of strut placement. In the BMSs cells only had to migrate short 
distances to cover the struts in comparison to the DESs which require cells to migrate 
the entire length of the stent. Therefore, the speed and reliability of endothelialization 
must be increased. Enhancing the rate of endothelialization can be achieved through 
the capture of circulating endothelial cells or enhancement of endothelial cell migration. 
This mirrors healing in the native vessel which occurs through the proliferation of 
resident cells and circulating endothelial progenitor cells. The two major methods to 
accomplish this are to increase the speed of migration and proliferation of cells once 
they are on the surface of the stent and to recruit cells to stent surface which can be 
achieved through several modalities such as the incorporation of growth factors, 
biopharmaceuticals, advanced surface topography, and binding motifs. Paradoxically it 
should be noted that enhancing endothelialization can lead to side effects such as 





Stent Design and Development 
2.1 Introduction 
In the field of stent development, there are tradeoffs between material selection, 
stent design, and fabrication. The goal of this work was to develop a stent platform that 
utilized a novel recombinant elastin mimetic protein polymer as the stent material. To 
successfully develop a novel stent platform from protein based materials, several 
benchmarks had to be achieved. In this Chapter we will explore different designs and 
validate or invalidate the designs based on their ability to perform the necessary 
stenting functions.  
The wide array of stent designs currently being researched has been driven by 
patent and marketing issues rather than actual scientific considerations in most 
instances[84]. Variations of the standard stent design have been used in academia 
because of the interplay of novel materials and a lack of fabrication modalities available 
to researchers in the academic setting coupled with the limited fabrication modalities 
that can be used on novel materials. This interplay of material selection and stent 
design has already been discussed in detail in Chapter 1.  
 To create a viable stent platform that can compete with current standards, there 
are a several benchmarks that must be achieved (Table 2.1). The benchmarks are 
necessary for a stent to be successfully delivered to the target vessel, perform its 
physical function, and not cause unfavorable biological responses. Stents must possess 
certain physical properties that allow them to perform their function. The first property is 
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a reliable expandability which minimizes size mismatches and prevents the stent from 
migrating down the vessel. A stent must also possess a threshold radial strength to 
maintain vessel patency. Stent coverage consists of two parts: firstly it is necessary to 
act as a scaffolding and prevent plaque prolapse, and secondly it must not block or 
prevent blood flow to collaterals. Finally, since the stent is placed in the lumen of the 
vessel, the thickness must be minimized to maintain an open lumen.  
Table 2.1 Design Considerations 
 Endovascular delivery requires the stent to be flexible enough to allow surgeons 
to track the stent through tortuous vessels, to possess a low radial profile allowing them 
to travel through plaque laden arteries, and cross the narrowed lesion site. The stent 
must also remain cinched on the balloon so it does not migrate off of the balloon. 
Finally, stents must possess radiopaque agents to allow for the proper visualization 
during plcament.   
Elastin mimetic protein polymers are known for their favorable biological 
properties. The design and development of a stent platform based on this material 
required exploring the biocompatibility, thromboresitivity, drug delivery kinetics, and 
endothelialization potential. Previous reports have spoken to the biocompatibility[85, 86] 
and thromboresitivity[46, 47] of this material, and these advantageous properties were 
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the reason that the material was developed into a novel stent platform. The next set of 
biological properties that an ideal stent possesses is the ability to release drug to 
overcome restenosis and the promote endothelialization. These are crucial for 
overcoming the limitations of current stent platforms. The ability to create stents from a 
polymeric based material allows researchers to tailor the material to allow for not only 
drug delivery but also enhanced endothelialization. Enhanced endothelialization can be 
achieved through the incorporation of chemical or physical binding motifs.  
2.2 Materials and Methods 
Elastin Mimetic Materials 
The design, development, expression, purification, and preliminary 
characterizations of the elastin mimetic materials used to develop these protein based 
stents have been described elsewhere[87]. Briefly, the elastin mimetic material is 
composed of a 58 kDa hydrophilic central midblock composed of 28 repeats of the 
elastic sequence [(VPGAG)2VPGEG(VPGAG)2] flanked by 75kDa hydrophobic 
endblocks composed of 33 repeats of the pentapeptide sequence[IPAVG]5. To allow for 
enhanced crosslinking the residues [KAAK] were located at the C terminus and between 
the midblock and endblock.   
Design Development and Fabrication 
Stent patterns were fabricated by a casting and laser ablation process detailed in 
Chapter 3. In brief, 100mg/ml lyophilized elastin mimetic material in 2,2,2-
Trifluoroethanol was cast into PDMS molds, and webbing was removed via a excimer 
laser ablation process. The planar sheets were then wrapped around a teflon mandrel, 
and the overlapping edges were solvent welded. In the initial studies on radial 
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expansion and mechanical properties, all stents were crosslinked via vapor phase 
glutaraldehyde crosslinking. In the second round of mechanical studies, the stents were 
crosslinked with solution phase genipin. 
Expansion Ratio 
The reliability of the expansion process was determined by measuring the stent 
after fabrication, crimping, hydration, and balloon expansion. After 1 week, stent recoil 
was measured. Once the stent was fabricated, it was removed from the forming 
mandrel, and the diameter was measured at 0º, 45º, 90º, and 135º. The stent was then 
crimped down, and the diameter was measured as noted previously. The stent was then 
hydrated in 37ºC PBS and imaged at 1, 10, 30, and 60 minutes. The stent was then 
balloon inflated using a 1.5mm, 3.0mm or 6.00mm balloon. The balloon was then 
deflated and withdrawn from the lumen of the stent and the diameter was imaged. The 
stents were then left in PBS azide for 1 week, and the diameters were imaged again to 
determine recoil. All images were then analyzed using image J software to determine 
expansion ratio and percent of expansion related to hydration. 
Collapse Pressure Testing
The collapse pressure system was based on a design detailed elsewhere[88]. In 
brief, a chamber was fabricated that allowed for the stent to be deployed in thin wall 
tubing that served as a mock vessel. Once deployed, the pressure surrounding the 
vessel was increased until the stented tubing collapses. The pressure is then released 
through a release valve, and the stent is tested two subsequent times.  
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Crimping the Stent 
Several crimping methods were explored and were dependent on design of the 
stent that was crimped. The crimping strategies were examined to determine the 
reliability of their crimp, the creation of failure points, and the achievable crimping ratio.  
The coiled stents were crimped down by placing them on a mandrel with the 
desired crimped diameter. The stents were crimped down in the hydrated state, secured 
in that position and dried. The dried stents were removed from the mandrel and placed 
on the balloon catheter. The interlocking stents were assembled with an outer diameter 
similar to those of the crimped stents.   
In the crown and connector design, the stents were crimped down in a variety of 
ways to minimize the radial profile and stress on the stent. The techniques used 
included manual crimping, belt crimping, and folding. Manual crimping of the stent was 
achieved by placing the stent on the balloon catheter and wrapping the stent in a pieced 
of aluminum foil. The foil wrapped stent was then crimped down by hand. The belt 
crimping setup consisted of a mylar sheet that was placed through a thin slit in a round 
piece of acrylic(Figure 2.6B). The stent and balloon catheter were placed in the lumen 
of the mylar sheet and diameter of the sheet was decreased. The final method og 
crimping was to pleat and fold the stent. To place pleats in the stent, a variety of 
techniques were used including vacuum pleating, funnel pleating, and manual pleating. 
Vacuum pleating was achieved by placing the stent on a die as shown in Figure 2.6. 
The stent was placed over the die, and a thin sheath was applied over the stent and 
connected to a vacuum source. The stent was then vacuumed on the die. The second 
way was to push the stent through a funnel with fins that pleated the stent as it was 
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pushed through. The final method was to use surgical tweezers to pleat and crimp the 
stent. The repeatability of the system was determined by the uniformity of the process 
and the repeatability of the final crimped structure. The radial profile was then examined 
by a ccd image acquisition system. The pictures were then brought into ImageJ and the 
diameter was measured at 0°, 45°, 90°, and 135°.  
2.3 Results and Discussion 
 The protein polymers have the potential to be tailored to possess all of the traits 
necessary for a successful stent(Table 2.1). The physical characteristics were vetted 
first by exploring the potential to design a stent with reliable expandability and sufficient 
mechanical properties. Once these parameters were achieved, potential crimping 
methods were investigated to achieve the necessary delivery parameters. Finally, the 
ability to enhance the stent’s performance by the selective incorporation of different 
factors was explored. 
Stent Design: There are several standard designs that are employed by 
commercial stent manufacturers and researchers alike. Several of which were reviewed 
in Chapter 1. All designs have advantages and disadvantages and must be evaluated 
based on the design criteria outlined in Table 2.1. The three major designs explored 
were the coil stent design, the interlocking design, and the standard crown and 
connector design. The coil stent design has relative ease of fabrication and proven 
utility in the academic space [89, 90]. The interlocking design works without the need for 
plastic deformation and has been successfully utilized by the REVA group and 
Advanced Vascular. The connector and crown design is the most common stent design 
and is used, in some configuration, for most commercial stent platforms.  
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Coil: The helical coil design has been used by several research groups to show 
proof of principle when using a new biomaterial for a stent platform. The helical coil 
consists of a strip of the material of interest wrapped around a mandrel and then set in 
place via some type of physical or chemical modification. This design offers the 
potential for easy modification as it is created from a planar sheet and therefore 
modifications can be carried out to improve both its biological and physical 
characteristics.  
Interlocking: The slide and lock design was also studied because of its potential 
to be fabricated from planar sheets. As will be discussed further in Chapter 3, the ability 
to fabricate a stent from a planar sheet and crimp it down in a facile manner allows it to 
overcome many of the development hurdles. From a design standpoint, this stent offers 
the advantage of locking onto itself to prevent recoil. This slide and lock design has 
been seen in the REVA medical stent[91] as well as a ratcheting modification of this 
stent in the nitinol form. 
Generic Design: The vast majority of commercial stents consist of a crown and 
connector design. We used a MicroCT to obtain the exact dimensions of a commercially 
available nitinol and SS stent platform. This technique allowed us to reverse engineer 
designs based on current nitinol and SS commercial stent platforms. This starting point 
allowed for the comparison of a stent fabricated from elastin mimetic material with the 
materials currently used in the industry. The two commercial stents examined were the 
Boston Scientific Express Stent, which is made of 316L SS and has a length of 27mm, 
and a diameter of 6mm, and the IntraTherapeutics Protégé Carotid Stent, which is 
made of Nitinol and has a length of 40mm and a diameter of 6 mm. Current metallic 
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stent platforms have been revised over the years to obtain these designs. Since, these 
designs have been conceptualized for well known benchmarked materials, it would be a 
flawed approach to simply base the elastic mimetic design on these designs and expect 
them to perform competitively. The material properties of the elastin mimetic materials 
are so different that radically different designs needed to be considered. To increase the 
strength of stents fabricated from our material, we explored changes to the industrial 
stent platforms. The design we used maintained several crowns connected together and 
also incorporated several changes such as strut width and overall geometry.  
Modification of Generic Design: In commercial stents, the width of the struts is 
usually a 1 to 1 ratio with the thickness of the stent. However, we did not want to 
increase the thickness of the stents so the only parameter changed was the strut width. 
The number of rows was decreased to keep the length of the stent standard as the 
circumferential strut width was increased. As mentioned earlier, the longitudinal strut 
widths were kept the same to maintain the pattern of the stent. This change created a 
stent design that was able to perform at an acceptable level as shown in the mechanical 
testing section.  
Early in the mechanical testing process, solid thin walled samples performed very 
well in the collapse pressure tests. Therefore, it was hypothesized that if we would 
incorporate solid rings into the stents, we could overcome the limitations of solid stents 
and still achieve better mechanical properties. We attempted to leverage the strength of 
the thin walled tubes by incorporating ring segments into the stent. Since our material is 
fairly compliant, a design that incorporates rings should still allow for crimping and 
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expansion of the stent. To attain the necessary trackability, the width of the rings was 
kept small and connected by a stent matrix of connectors and struts.  
The other modification that was explored was decreasing the cell size and 
increasing the cell number of the stent. Table 2.2 shows the critical design dimensions 
of these stent systems. A decrease in cell size was thought to allow for stiffer stents 
because the fenestrations in the stent are smaller. In order to do that, the stent cell had 
to be scaled down according to diameter to get proper stent coverage. Due to the 
geometry of the stent a 200m width would not work so the top of the top of cell was 
blunted as shown in Figure 2.3 to allow for a connector width in line with the earlier 
models. This shortens the top and the bottom of the cell by 165µm and decreases the 
total height of the cell by 330m. This change allowed for a connector width of 533m 
and an increase in connector length from 342.5m to 1.178mm. 
Figure 2.1. 1.5 mm and 6 mm stent designs (all dimensions are in mm) 
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Diameters: Stents are currently deployed in vessels with a wide range of 
diameters and, as such, a range of stent diameters exist in the market. Different stent 
designs and materials are best utilized at different diameters, and therefore, we sought 
to ensure that our methods could be used to fabricate a wide range of stent diameters. 
The initial diameter developed was the 6mm stent for two reasons. Firstly, these are 
common sizes for elastic stents placed in peripheral vessels that can be subjected to 
crushing blows, thereby allowing them to recover their shape and not be deformed 
requiring corrective surgery. Secondly, the 6mm stents were easier to fabricate, 
manipulate, and test in all of the outlined endpoints. The fabrication methods that were 
used had the potential to create stents with different diameters. In order to change the 
diameter on the crown and connector design, the cell had to be scaled down according 
to the final desired diameter to get proper stent coverage as is commonly done with 
commercial stents.  Alterations to the cell size also caused changes to the connector 
width so they were modified as shown in Figure 2.3.  
Thickness is not a variable that was greatly altered as the ideal stents should 
always minimize the thickness of stents and the final design will use the thinnest stent 
that still yields acceptable collapse pressure values. That is why the stent with solid 
rings appeared to be the best option because it allows for a minimal thickness and still 
has mechanical properties in excess of what is needed. In the original testing with the 
6mm stents, a thickness of 200µm was utilized and in the later studies that focused on 
the 1.5mm stent a thickness of 100µm was utilized. 
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Table 2.2 Stent parameters  
Reliable Stent Deployment 
Reliable stent deployment consists of consistent expansion with minimum 
recoil to ensure the stent will keep the lumen of the vessel patent. The ability to expand 
with a known diameter is important, allowing the clinician to select the proper stent for a 
given vessel. The rate of expansion must be sufficient to allow the stent to be deployed 
without migrating in the vessel or blocking the vessel blocked for too long during the 
procedure. Finally the stent must remain in the final deployed state and not recoil 
significantly which has been a limitation of bioabsorbable stent platforms[92]. 
Rapid and reliable expansion is usually achieved through the use of a balloon 
catheter or the utilization of a stent’s shape memory properties. Balloon-expandable 
stents are made from materials that can be plastically deformed through the inflation of 
a balloon. After the balloon is deflated, the stent remains in its expanded conformation, 
except for a slight recoil caused by the elastic portion of the deformation. The ideal 
material for these stents therefore has a low yield stress, making it deformable at 
manageable balloon pressures, and a high elastic modulus for minimal recoil. Stainless 
31 

steel is the most common form of balloon expandable stent. The other major expansion 
type is shape memory, or self expandable, stents. These stents are made from material 
that can exist in two phases: the pre-expanded and post-expanded. Self-expanding 
stents are manufactured in the expanded form, crimped down on a delivery system, and 
constrained by a sheath. Upon removal of the sheath, the stent expands to its original 
diameter. Shape memory is usually considered a material property of the chemical 
structure and is mostly known to be temperature dependent. 
Initial studies on stents fabricated from the elastin mimetic material showed that 
the stent could elastically recover most of its shape after it was crimped down, as long 
as it remained hydrated. In brief, a stent crimped and constrained in the hydrated state 
will regain its pre-crimped diameter when unconstrained. If the stent is crimped, 
constrained, and dried, then the stent does not regain its shape when unconstrained. 
However, upon rehydration, the stent reverts back to its pre-crimped diameter. It should 
be noted this is not simply an effect of the material hydrating and swelling, as stents that 
were fabricated at a smaller diameter and not crimped but subjected to the same 
crimping drying process did not expand upon hydration. In this system, the stent can be 
crimped down to a minimal diameter, confined and dried down, and upon hydration, the 
stent expands to 70% of its fabricated diameter.  
 A literature review discovered that other research groups have explored the 
potential of shape memory effect based on the hydration of a material. Chen et al. 
showed the potential to create a stent from a modified chitosan-based material that, 
upon exposure to water, the stent expanded in minutes[93].  Also in the area of 
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hydration strain recovery, Jung et al. demonstrated water-induced shape recovery in 
polyurethanes containing a strongly hydrophobic moiety in the hard segment[94]. 
There are some stents that use both expansion mechanisms. These are usually 
materials that can self-expand but the rate of that self expansion is not fast enough to 
deploy the stent on the minute time scale. In these cases, a balloon is used to expand 
the stent which allows for the fast deployment of balloon expandable stents with the 
added feature of outward expansion, coming from the self expansion of the stent, in the 
vessel that prevents recoil that has plagued polymeric stents. Since, the elastin mimetic 
stent possessed some shape memory, but the recovery rate and time are not sufficient 
for stenting, we employed a combination of balloon deployment and self expansion.  
The first critical design variable that was explored was whether to fabricate the 
stent in the expanded diameter and crimp down or fabricate the stent with a nominal 
diameter and expand to the necessary dimensions.  In previous reports, recoil of 
polymeric stents was a limitation in elastic stent design. Based on the elastic properties 
of the elastin mimetics compared to metallic stents, we hypothesized that the stent 
would have to be fabricated in the expanded diameter as the material has mostly elastic 
properties and trying to expand it would lead to severe recoil.  Table 2.3 shows the 
results of our expansion test.  
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Table 2.3 Stent Expansion Studies  
 To explore the potential of expanding the stent from a nominal diameter, a coil, 
ratchet, slide and lock, and three generic stent design were fabricated with a nominal 
diameter and expanded. The C2B helical stent was fabricated at a diameter of 2mm and 
was expanded to a diameter of 6mm. It is clear that the hydration of the stent does not 
expand the diameter of stent fabricated with a nominal diameter. This design also has 
mostly elastic deformation, as the recoil is approximately 45%. The ratchet design did 
not appreciably increase in diameter after hydration and, after balloon expansion, 
showed significant recoil at 30%. The slide and lock design allows the stent to be 
expanded, in theory without plastic deformation and revolves around the ability to 
expand the stent with ratcheting teeth lock each progressive position. The problem with 
this approach was that we could not get reliable expandability. The major limiting factor 
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seemed to be the failure of the ratcheting mechanism causing the gears to get stuck, 
which resulted in the stent tearing or stretching as the balloon was inflated, which in turn 
caused large amounts of recoil when the balloon was deflated. Generic designs A, D, 
and Final were fabricated at the nominal diameter and expanded. Table 2.3 shows that, 
like most polymeric stents, the stents were not able to expand from the minimal profiles. 
Balloon expansion of nominal diameter generic stents resulted in tearing and failure of 
the stent. These results demonstrate that this approach was not feasible, and stents 
should be fabricated in the larger diameter. 
 Stents fabricated in the expanded form and crimped down showed reliable 
expansion and minimal recoil. The coil stent was easily crimped down to a diameter of 
2.09mm. Upon hydration, the stent’s diameter increased by 86%, and upon balloon 
expansion, the stent was expanded to a final diameter of 6mm with minimal recoil after 
48 hours. The ratchet stent design had similar hydration and balloon expansion as the 
coil stent. However, the failure of the stent to properly lock on itself caused it to have a 
recall of 8.3%. In the four generic designs fabricated at the 6mm diameter, all 
experienced no statistical difference at the different parameters of stent expansion. The 
stents were crimped from an average diameter of 5.75mm to a diameter of 2.45mm. 
Upon hydration, these stents averaged an increase of 50% over the crimped diameter. 
All stents were then balloon expanded to a diameter of 6.16mm and had an average 
recoil of 2.5%. The final stent design was fabricated with a diameter of 1.5mm and 
crimped down to a nominal diameter of 0.89mm. Upon hydration, the stent increased to 
a diameter of 1.14mm and then was balloon expanded to a diameter of 1.61mm. The 
recoil was also minimal at 1.3%. 
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The final measure of reliable expansion is the openness of the lumen. As 
mentioned above, the ability to minimize the thickness of the stent is paramount in 
ensuring lumen has the proper inner diameter. In the case of the helical coil, the 
material properties did not allow these stents to maintain their rigidity upon expansion, 
which caused some of the rings to overlap and not fully expand. This problem affected 
the thickness as the stent rings were overlapped increasing the stent thickness by a 
factor of 2 or more, leading to a narrowing of the vessel. The slide and lock design had 
a thicker profile based on its design, as it had some portions that overlapped. This is a 
problem as the blood could flow between the stents and ultimately cause part of the 
stent to prolapse into the vessel.  
Radial Strength/Mechanical Properties 
Once a stent is expanded in a vessel, it is subjected to an external pressure from 
the arterial wall. In order to keep the vessel expanded, the stent must be capable of 
withstanding these pressures. To determine this pressure, a collapse pressure setup 
has been postulated as the most representative way to quantify this pressure. Some 
groups have simply put the stent between two flat platens in a compression testing 
setup; however, in our opinion and several other researchers [59, 62-64, 95-100], this 
method is inferior to a collapse pressure setup. The required value of collapse pressure 
depends greatly on the vessel type and condition in which it is placed. Any stent design 
and material composition needs to attain a sufficient collapse pressure to prevent the 
collapse of the stent immediately after implantation and assure long term stability. 
Numerous researchers in the field of novel stent development have referenced the 
report by Agrawal et al., postulating the minimum collapse value that still provided a 
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safety factor was 300mmHg (39.98kPa)[59]. It should be noted that it is imperative that 
a stent has sufficient radial stiffness to allow for an open lumen; however, it is preferable 
for it to be adequate rather than have a high radial stiffness which induces unnecessary 
chronic trauma to the artery wall leading to an enhanced unfavorable biological 
response[101]. Therefore, we sought to achieve an acceptable collapse pressure with 
regard to the Agrawal et al. values but not a collapse pressure far in excess of that 
value.  
To determine if the protein based stent possessed the needed mechanical 
properties, a collapse pressure setup was constructed based on the design of Stack et 
al.[88]. The collapse pressure system, detailed elsewhere[88], consists of a chamber 
with four ports. A tube, consisting of two rigid tubes connected in the middle by thin 
flexible tubing, is placed through the two ports on either side. The lid of the chamber 
contains two ports which allows for injection of water into the closed system and 
monitoring the pressure inside the system. The stent is then delivered into the tubing, 
allowed to hydrate for 5 minutes in 37°C PBS, and t hen expanded to its full diameter. 
The system then has 37°C PBS circulated through for  5 minutes. The flow is then 




Figure 2.2 Collapse Pressure Setup 
The pressure in the chamber is then increased by pushing water into the closed 
system at 1mL/sec. Once the first sign of stent collapse is evident, the syringe pump is 
stopped and the pressure is allowed to go to zero by opening the relief valve. This 
allows the stent to recover its initial shape before it is collapsed again. This is performed 
three times is to get an average collapse pressure for the stent and to ensure the stent 
can be collapsed and not fail. In all of the collapse pressure experiments on the elastin 
mimetic stent designs a minimal value of n=3 has been used. Therefore for each stent 
design, we have at minimum nine values of collapse pressure. 
In the early stages of testing, solid thin walled tubes were used that were 
fabricated from dip coating. The thin walled tubes of elastin mimetic showed collapse 
pressures that were several times the needed collapse pressure proving the elastin 
mimetic materials, in their simplest form, had the necessary mechanical integrity(Figure 
2.4A). In these initial studies, two varieties of elastin mimetic materials were studied and 
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demonstrated that LysB10 has more favorable collapse strength than B9. These results 
were in agreement with the previous mechanical properties that were ascertained for 
this material([87, 102]). In addition to the noncrosslinked varieties, we also explored the 
effect that vapor phase and solution phase glutaraldehyde crosslinking had on the 
collapse pressure of the LysB10 constructs. The vapor phase crosslinking was capable 
of increasing the collapse pressure almost six fold, while the solution phase increased 
the collapse pressure three fold. This illustrates the pronounced effect of crosslinking 
and the differences between different crosslinking strategies. 
 It should be reiterated that these initial studies looked at thin walled tubes and 
not fenestrated stents. In the literature there is mechanical data from other fields that 
highlights the differences in collapse pressure of thin walled tubes and slotted thin 
walled tubes. When the fenestrations are placed in the stent, the collapse pressure 
decreased substantially. With these studies as a building block, vapor phase 
glutaraldehyde crosslinked Lysb10 was chosen as the material for the next set of 
experiments.  
 Initially we were going to explore variations of the designs discussed in earlier 
sections; however, failures in deployment and a lack of reliable expansion prevented the 
stents from being tested properly in the collapse pressure setup. Therefore, the stent 
design that will be focused on for the collapse pressure tests is the generic crown and 
connector design. Table 2.2 outlines the design paramteres that were used in the first 
round of testing. The first variable that we examined was strut width. In all of these 
experiments the thickness was maintained at 200µm, the length was maintained at 
15mm, and all materials were LysB10 crosslinked with vapor phase glutaraldehyde. 
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We hypothesized correctly that an increase in strut width would increase the 
collapse pressure of the stent(Figure 2.4B). The struts widths ranged from 250µm to 
750µm. The stent with 250µm struts had a collapse pressure of 6.93±0.46 kPA. This is 
obviously well below the 39.98kPa that is required. When the strut’s width was 
increased to 500µm, the collapse pressure increased to 19.43±0.90 which is a 2.8 fold 
increase in collapse pressure but still below the targeted collapse pressure. When the 
strut width was increase to 750µm the collapse pressure increased to 24.57±1.13, 
which was a increase of 3.5 fold over the 250µm strut. 
The high collapse pressure of the solid ring structures gave the design cue of 
incorporating solid rings into these structures. The generic stent design with 500µm 
struts had rings placed on the proximal and distal ends.  These solid segments 
increased the collapse pressure for the stents to 110.59±4.91 kPa and impart a 16 fold 
increase over a stent of the same design without rings(Figure 2.4C). This design was 
the only design that allowed us to get over the 39.98 kPa threshold that was determined 
to be the minimum collapse pressure of a stent. In fact, the stent with rings has a 
collapse pressure  2.7 fold above the threshold value. 
The finally design cue examined in the first round of testing was the ability 
fabricate stents with different diameters and the effect this change has in collapse 
pressure(Figure 2.4D). A decrease from 6mm to 3mm in diameter, when all other things 
were kept the same, resulted in an increase in the collapse pressure value of the 3mm 
stent to 20.75±1.41kPA a 3 fold increase. This could prove advantageous as we could 
create thinner stents in the smaller diameter stents.   
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Figure 2.3 6mm Stent Designs with a 200µm thickness (A) Different elastin mimetic 
materials and crosslinking strategies (B) Changing the strut widths (C) Stents with and 
without rings (D) Altering the diameter but keeping the same design and thickness 
200µm 
The next round of mechanical testing highlighted in Figure 2.4 was performed on 
a 1.5mm stents crosslinked with genipin. As discussed in the in vivo portion of this 
thesis, the rat aorta was a model of interest and ultimately the animal model that we 
chose. Since, their vessels are small, we wanted to prove that we could fabricate a 
1.5mm stent capable of having an acceptable collapse pressure. As with the previous 
results on the 6mm stent platform, the stent designs had a significant effect on the 
collapse pressures (Figure 2.4). In these tests we explored four main changes to the 
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1.5mm stent design; increasing the strut width from 250µm to 1000µm, decreasing cell 
area, incorporating rings, and changing the diameter. 
The collapse pressure increased with increasing stent widths. The 500µm strut 
width had 2.84 times the collapse pressure of the 250µm wide strut design and 0.48 
times the collapse pressure of the 1000µm wide strut design.  
The second variable that was explored was a change was a reduction in cell 
size. The modification of cell size also significantly affected the collapse pressure.  A 
cell size reduction of 50% increases the collapse pressure by 3.19 times.  
As with the larger stent rings were incorporated into the design, however, as 
noted in Table 2.3, it is evident that the number of rings used was different, as well as 
the width of the rings. To achieve significantly higher collapse pressure while minimizing 
surface area of the stent, rings were incorporated into the stent structure. The rings 
imparted 3.05-fold increase in collapse pressure. The structure with rings had 
significantly higher collapse pressure than any other design. The other variable that was 
explored was the affect of the diameter on stent development. Figure 3 panel D shows 
that maintaining all design aspects and increasing the diameter of the stent causes a 
decrease in collapse pressure. Compared to the 1.5mm stent, increasing the stent 
diameter to 3mm decreases the collapse pressure by 1.70 times, and increasing the 
stent to 6mm decreases it 3.48 times. This shows the need to alter design specifications 
to get a necessary collapse pressure. 
The purpose of this research was to explore and validate the 1.5 mm stent 
design. However, in the previous experiments, we demonstrated that a decrease in 
diameter would yield a stent with higher collapse pressure. In this instance we 
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increased the size of the stent to look at the effect of collapse and noted a similar trend. 
For, the purposes of this report we did not optimize a design for the larger diameter 
stents.  
Figure 2.4. (A) Collapse pressure for stent with different widths, (B) collapse pressure 
for stent designs that have different cell sizes, (C) collapse pressure for stent designs 
without and with rings, and collapse pressure of stent design with ring fabricated into 




In order for a stent to perform its needed functions, it must be capable of being 
delivered and deployed at the site of vessel narrowing. Radial profile is one of the most 
important parameters of stent delivery because stents must travel through tortuous 
vessels that are often partially occluded. To achieve a minimal radial profile, a process 
was developed to crimp down the stent. Several crimping strategies were explored to 
allow for stents fabricated in the expanded form to be crimped down to an acceptable 
radial profile. To determine the efficacy of each method, the endpoints that were 
examined were repeatability, creation of failure points, and radial profile. The 
repeatability was determined by examining the crimped profile and determining whether 
the stent is being crimped in a repeatable pattern or if the stent undergoes random 
crimping. The next endpoint that was examined qualitatively was the amount of stress 
that the stent is subjected to during the crimping procedure. The goal was to minimize 
the stress with controlled crimping and eliminating areas of high stress, such as, tight 
corners and out of plane bending. As suspected, this qualitative value correlated to the 
creation of failure points very well. Finally, the radial profile was determined by 
measuring the stent at 0º, 45º, 90º, 135º, and 180º. The widest point of the stent was 
taken to be the minimum profile. 
Crimping Setups  
Several crimping strategies were explored ranging from those used in the 
stenting industry to those that have been explored by other researchers. Most of the 
current stent crimping methods exploit the stent’s repeating cell pattern and minimize 
the size of the stent’s open cells, as shown in Figure 2.6.A, to achieve their ultimate 
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goal of a decreased radial profile. In most cases, the crimping system applies a force to 
the stent equally in the circumferential direction which allows the stent’s cells to close, 
decreasing the outer diameter of the stent. The current gold standard in commercial 
stenting shown in Figure 2.6 A is not applicable to crimp current elastin mimetic stent 
designs because the geometries of the new stent designs prevent hinging at the joints. 
Most commercially available stents have a width to thickness ratio of one, whereas our 
new designs have a much higher ratio and therefore, successful crimping strategies 
must crimp the stent without making the cells smaller. 
The first technique used was manual crimping. This technique has it roots in the 
early adoption of stenting as a way for physicians to secure a stent to a balloon and 
allow for a small radial profile.  The elastic component of the stent material provided a 
challenge to manually crimp the stent. To prevent the stents from returning to their 
original diameter, they were wrapped with aluminum foil. This allows for the system to 
be a malleable process, similar to the way stainless steel stents can be crimped down. 
However, the process resulted in subpar radial profiles, lacked repeatability, and 
created failure points in the stent. Also the stent was not secure on the balloon, and 




Figure 2.5 (A) Commercial Crimping Strategies, (B) Mylar sheet crimping strategy, (C) 
advantage of pleating the balloon with regard to radial profile (D) die for pleating balloon 
and stent, (E) Funnel pleating device to pleat the balloon, (F) Pleated Balloon, (G) stent 
on balloon before pleating (H) folded Stent (I) wrapped stent 
The second method consisted of a sliding Mylar belt that went around an 
uncrimped stent and balloon catheter assembly and through a thin slot in a rigid acrylic 
block. A downward force was placed on the Mylar sheet which decreased the diameter 
of the Mylar belt, thus crimping the stent onto the balloon. There was a limit of about 
2.3mm for the final diameter. This method also did not cinch the stent on the balloon 
very well and therefore traveling the vessel would be difficult. 
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When the prior two crimping procedures were examined it, became obvious that 
the process occurring was akin to pleating the stent. Since this was occurring, we 
sought to control this pleating so the stents would be crimped in a reliable manner and 
stress on the stent could be minimized. The process consists of placing pleats in the 
stent and then folding these pleats around the center of the catheter to create a minimal 
profile. It is obvious that the creation of multiple pleats can dramatically affect the 
diameter of the stent without further adjustment (Figure 2.6C). However, in the case of 
stents, the rigidity and thickness limit the number of pleats that could be formed. Instead 
we focused on creating two, three, or four pleats depending on the outer diameter of the 
stent.  
The pleating was achieved by three processes: the first was to pleat the stent by 
passing the stent through a funnel type pleating device, the second was to place a die 
inside the stent and apply vacuum, and the third was to form the pleats by hand. The 
first pleating technique used a funnel like device to form pleats on the stent(Figure 
2.6DandE). This technique allowed for the creation of pleats on the balloon and stent. 
The main advantage of this technique is the ability to pleat the stent and balloon 
simultaneously which allows the stent to be intertwined with the balloon and prevent the 
stent from slipping on the balloon during delivery. The second pleating strategy 
consisted of placing a die on the inside of the stent and using an applied vacuum to 
form the stent. The biggest limitation of this process is that the pleating does not take 
place on the balloon. The final pleating technique formed pleats by hand using surgical 
tweezers. This option has been used on the smaller stent profiles to ensure the stents 
are not damaged and to create tightly wrapped structures. Table 2.4 summarizes the 
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endpoints of the crimping process and shows that overall the pleating and folding 
techniques have been very success in producing repeatable crimping and minimal 
radial profiles. Crimping by hand seems to be the best method as it allows for the stent 
and the balloon to be intertwined, keeps the stent from slipping off the balloon, and 
prevents major stresses from being imparted on the stents. It should also be noted that 
the crimping ratio decreases as the stent diameter decreases because the smaller 
stents are more difficult to crimp and the intrinsic size of the catheter does not change 
among the different diameter groups.  
Table 2.4. Crimping strategies  
2.4 Conclusion 
Using a novel material, we were able to create a stent design that leverages the 
strength of the elastin mimetic material and minimizes the material’s limitations. This 
required the design and development of a novel stent platform. This stent also required 
novel crimping methods to allow for the production of a deliverable stent. These stents 
have proven to have reliable expansion and minimal recoil. These stents have also 
shown that they possess the required mechanical properties for stent deployment.  
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Final Stent Design: The ultimate stent design that we have moved forward with 
consists of solid rings that have a width of 1.5mm with stent mesh pattern and a total 
length of 7mm(Figure 2.6) 





Fabrication of Protein Based Materials 
3.1 Introduction 
The utilization of biological materials provides a promising approach for 
attenuating deleterious responses to current implantable medical devices. However, 
despite considerable research advances over the past decade, these materials are still 
mainly limited to injectables versus fabricated devices. Compared to bioabsorbable 
polymers, biological materials pose challenges that are not easy to overcome, and their 
attributes can lead to a hindrance in fabricating devices. As far as we know to date, 
there has been a lack of fabrication of patterned robust films made from native 
materials. We describe herein the development of mechanical robust constructs from 
biomimetic materials for use in cardiovascular stenting.   
Stent Fabrication 
 Laser machining of stents from thin walled tubing is the most common form of 
stent fabrication.  Stents can be machined through a direct write method, where the 
laser is focused directly on the substrate, or a masked projection method in which the 
laser passes through a mask before hitting the substrate. Laser micromachining creates 
stents by removing material to create open cells via sublimation, melting, or oxygen 
reaction.  Sublimation is not commonly used because the cutting speed is slow.  
However, this technique does minimize the adherence of solid impurities, or dross, and 
the extent of the heat affected zone in which adjacent microstructure and mechanical 
properties are altered by heat.  Melting and oxygen reaction remain industry standards 
because of their high processing speeds, but often lead to the deposition of the 
removed material on the surface, oxidation at the cuts, and burr formation.  Dross and 
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spatter that stick to the backside of the cut can be removed with additional finishing 
steps, such as microblasting with aluminum oxide powder, pickling, or soft etching.  
Schemes to manipulate laser type, pulse length, power level, and different mediums 
that contain the laser, have been sought to address these drawbacks.   
 The neodymium:yttrium-aluminum-garnet (Nd:YAG) solid-state laser is the most 
frequently used laser for stent fabrication because of its short fundamental wavelength 
of 1064 nm.  Nd:YAG lasers have been shown to make slits on the order of 50 - 100 m 
with short pulses and high repetitions [103]. The main drawback of the Nd:YAG laser is 
the size of the heat affected zone and dross adherence. Metallic materials exhibit 
exceptional absorption of infrared (IR) light, which allows for efficient and rapid 
machining with IR lasers.  However, bioabsorbable polymers are optically transparent, 
therefore different lasers are required. Femtosecond and excimer lasers are capable of 
machining optically transparent materials, such as bioabsorbable polymers with high 
fidelity[104]. Femtosecond lasers are usually based on the titanium:sapphire solid state 
laser and can machine objects on the nanometer scale with a cut width of 30 µm on 
nitinol [105, 106]. The femtosecond laser has also been used to fabricate biodegradable 
magnesium alloy stents [107]. Their major shortcoming is cost. Excimer lasers do not 
cause ablation by heat but through disruption of molecular bonds through absorption of 
laser light in the ultraviolet range.  While adverse heat effects do not exist, lateral 
resolution is about 10 m with beam quality not as good as other laser systems [108].  
Polymeric stents have also been machined using CO2 lasers [109, 110].  However, CO2
lasers may induce chemical changes in the treated material [111]. 
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 Laser parameters that can be varied are the pulse length and energy level.  
Pulses longer than 10 ns are associated with heat diffusion and conduction, which can 
impact the properties of material in the vicinity of the pulse beam (Fig 3.) [112].  Shorter 
pulses, in the femtosecond range, and higher pulse repetition reduce the heat affected 
zone, which is especially critical for polymeric materials [113].   
Photoetching, Electroforming, and Microelectrodischarge Machining for 
Fabrication of Metallic Stents 
 Alternative stent manufacturing techniques include photoetching, electroforming, 
and micro-electrodischarge machining (EDM), which are capable of producing 
burr/dross free cuts with minimal roughness.  The EDM process has been used to 
fabricate stents from planar 50 m thick stainless steel foil [114] and demonstrate the 
capacity to incorporate sensor systems to monitor intravascular pressure and flow [115].  
Photochemical etching uses a photoresist and etchants to chemically remove 
unmasked material from metallic sheets or tubes in order to produce complex designs 
with high resolution[116]. The stainless steel NIR (Boston Scientific, Inc), the stainless 
steel LP (Interventional Technologies, Inc) [117], and the nitinol aSpire (Vascular 
Architects, Inc.) stents were produced via this process. Photochemical etching has also 
been used in the fabrication of an origami  stent fabricated from nitinol foil [118] and in 
conjunction with 3D lithography to produce patterns on nitinol films formed via 
magnetron sputtering [119, 120]. 
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Fabrication of Polymeric Stents 
Laser machining has been used to produce polymeric stents, such as the 
REVA™ stent [121]; however, concerns related to thermal or chemically induced 
alterations in polymer properties have motivated the evaluation of injection and 
compression molding processes.  These techniques are particularly suitable for 
polymeric materials because of their thermoplastic behavior with recent efforts directed 
at optimizing micro- and nanomolding processes [122-126].  Solvent cast films have 
been fabricated into stents by cutting the films into strips and wrapping them around a 
mandrel into a coil like structure [127]. As a related process, fused deposition molding 
(FDM), which consists of repeated deposition of thin layers of polymer, has been 
evaluated for the production of 3D microstructures that display micron level resolution 
with short processing times [128].  Likewise, melt spinning has also been used to form 
bioabsorbable polymer fibers on the range of 150 m to 200 m which can then be 
woven or knitted into stent-like structures [97, 129].  The technique of controlled 
expansion of saturated polymers allows for drug loading during the fabrication process 
[130] and can form bioabsorbable stents that posses proper mechanical integrity [131]. 
To date, photolithography has been used to produce biodegradable scaffolds for tissue 
engineering applications, but has not been utilized in the fabrication of stents. 
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Table 3.1 Literature Fabrication Table of Stent and Scaffolds  
Our Fabrication Process 
In these studies we explored the use of excimer laser fabrication and PDMS 
molding. Excimer laser has proven to be a valuable tool in the biomedical field because 
of its ability to ablate the material it contacts without heating the surrounding material 
making it a cool laser. Excimer lasers are able to ablate biological materials by 
projecting a tightly focused UV beam onto a substrate which breaks down the molecular 
bonds of organic materials. The heat that is created is usually dissipated as the material 
is ablated the potential to ablate biological has been expertly reviewed[132]. The 
applicability of patterned biological materials is evident when one explores the medical 
device industry. From stents to bladder meshes there exists product that require the 
interplay of fenestrated materials. The advantage of these materials is the potential to 
add another knob to allow for the modulation of their mechanical properties. It has been 
shown that placing holes in polymers allowed for an increase in compliance[133] of 
blood vessels.   
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This Chapter focuses on the fabrication techniques used to create a protein 
based stent. This is a platform technology that has already been used in several diverse 
applications relating to other thesis and grant work. This section will explore the 
potential to create protein sheets with fenestrations and then form these sheets into 
stents.   
3.2 Materials and Methods 
Production of Elastin Mimetic Materials
The design, development, expression, purification, and preliminary 
characterizations of the elastin mimetics used in these experiments has been described 
elsewhere[87]. For all of the analysis, films were solvent cast from 100mg/ml lyophilized 
protein, LysB10, in 2,2,2-Trifluoroethanol (TFE) at room temperature, unless otherwise 
noted.  
Excimer Laser Approach 
The excimer laser setup consists of an excimer laser (Resonetics Inc., Nashua, 
NH) operating at a wavelength of 248 nm with a pulse duration of 20ns and a frequency 
of 60Hz. Parameters such as power, demagnification, spot size, pulse number and 
speed were selected based on the fabrication design and whether the laser was used in 
the direct write method or masked method. A LysB10 film was attached to a quartz 
substrate that was (10cm x 10cm ) and placed onto sliding stage below the laser.   
The ideal laser parameters used to ablate the elastin were determined using a 
characterization protocol described earlier [134]. In brief the quartz and elastin film was 
placed on the stage in the excimer laser and a 10 × 10 matrix of laser shots were fired 
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onto the protein film using a 20 m laser spot size. A sample of this characterization 
protocol can be seen in Figure 3.1 panel B. As noted on the picture with each shot the 
power was increased in the Y direction and number of pulses in the X direction. The 
ablation depth of each hole was measured using an optical microscopy setup with depth 
evaluation software.   
Figure 3.1. (A) Ablation depth vs. pulse number curve for 10 energy levels, (B) SEM 
micrographs of EM ablated holes with an increase in pulses in the x direction and 
energy in the y-direction  
The laser energy was determined by multiplying the energy(mJ) by the 
transmission. The energy used was 200mJ and the power transmission was 75% 
resulting in a laser spot energy was 150mJ. The focal area for the 3mm square mask 
was 0.0056cm2, and the focal area for the 200µm mask was 0.0000196cm2. The 
fluence of the laser was calculated by dividing the laser spot energy by the focal area 




Direct write method conditions 
In the direct write setup the CAD file of patterned design was uploaded into the 
laser operating system. Using the laser program the CAD file was turned into a 
coordinate system that allowed the laser to trace all edges of design creating 
fenestrations. A spot size of 25µm was used.  
Masked Method Conditions 
 Creation of a pattern mask was made by designing the pattern in CAD and then 
transferring it to the IR laser. The mask was fabricated from stainless steel so it could 
be sterilized since it contacts the protein material. An additional step in this process is 
that the mask is placed over the protein film and attached to glass substrate to keep the 
mask aligned.  
The masked ablation setup consists of a laser mask with a 3mm x 3mm spot 
size, a demagnification of 4x, a mask of the patterned design, a protein sheet, and a 
glass substrate. A rastering sweep of the laser was used to ablate the portions of the 
protein film not covered by the mask. The program makes the laser raster the entire 
length of the mask, then the laser moves down by 0.75mm and rasters another line the 
entire length. This command is continued until the laser has rastered the entire width of 
the construct. The laser then returns to the origin and moves up 0.375mm and rasters 




Figure 3.2. Schematic of Excimer Ablation  
Fabrication and Utilization of PDMS Molds  
All patterns were designed in AutoCAD and imported into the LSL550 program 
that runs the CO2 laser (LS500 Laser Engraving System, New Hermes-Gravograph Inc., 
Duluth, GA). The laser was then run in the raster mode to create the acrylic molds as 
shown in Figure 3.3. A power setting of 20% was used, and the number of passes 
varied from 3 to 12 and the corresponding depths ranged from 100um to 1mm. The 
acrylic was then cleaned with compressed air and isopropyl alcohol. Optical 
characterization was used to ensure the molds had the proper geometry. The mold was 
then placed in an aluminum reservoir and premixed PDMS (Sylgard 184, Dow Corning) 
was poured onto the acrylic molds and placed under vacuum for 45 minutes to ensure 
the PDMS was pulled down into the mold and all trapped air was removed. The molds 
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were then placed in the oven at 80°C for 2 hours. T he PDMS was then allowed to cool 
for 1 hr at room temperature and demolded from the acrylic. 
Casting Elastin Mimetics in PDMS Molds 
The PDMS molds were sterilized with ethanol, and dried in a vacuum for 24hrs. 
Molds used for subsequent castings were also washed in TFE to remove any residual 
protein from previous castings. The casting material was LysB10 dissolved in TFE at a 
concentration of 100mg/mL. The PDMS molds were attached to a rigid substrate to 
prevent mold deformation. To cast the films solutions were aspirated into a 1ml BD 
syringe with an 18 gauge needle, degassed, and dispensed through a 25 gauge needle. 
The solution was syringed into the recesses of the mold until they were slightly overfilled 
with the protein solution. Care was taken not to overflow the mold to minimize webbing. 
The mold was filled either under 5X or no magnification depending on the shape of the 
3D structure. 
The molds were placed in Petri dishes that were subsequently closed and sealed 
with parafilm to decrease the rate of solvent evaporation. The solution was allowed to 
equilibrate for twelve hours in the closed Petri dish. The Petri dish was opened every 
four hours to release the vaporized TFE four times to provide for a gradual evaporation 
of the TFE. In processes that required multiple coats the casting conditions were 
followed again. These steps were repeated to get the desired thickness.  The raised 
portions of the PDMS mold were then wiped with a sterile TFE coated cotton swab. The 




To examine the effect of different casting conditions, several variables were 
examined independently to achieve optimal casting conditions. The variables that were 
explored were mold depth, evaporation time, casting solution concentration, and cast 
number. 
Combinatorial PDMS casting and excimer laser approach 
In the combinatorial approach the PDMS molds were overfilled with protein 





Figure 3.3 A combinational approach was used to generate stents from protein polymer 
solutions. (A) PDMS mold patterned with the stent design. (B) PDMS mold overfilled with 
elastin mimetic material.  (C) Mask placed on top of the webbing from the solvent casting 
(D) Elastin mimetic in mold after the webbing is ablated with an excimer laser. (E) A stent 
that has been unmolded. (F) A rolled and attached stent.  
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Optical Characterization of Micofabricated Protein Polymer Sheets 
To validate the fabrication processes, the patterned protein sheets’ surface 
morphology and thickness were examined using a scanning electron microscope (SEM) 
(Topcon DS-130F Schottky Field Emission SEM/STEM) and optical microscopy.   
Determination of Design Parameters 
Fabrication fidelity, and therefore dimensional stability, arises from the accuracy 
of the fabricated patterns. To determine the fabrication fidelity, the widths and thickness 
of the constructs were measured after different fabrication approaches.   
Determination of Cost Parameters 
The time required to fabricate a patterned sheet was calculated for each process. 
All times were the summation of time required to fabricate the device, including relevant 
times needed to evaporate solvents. Material waste was calculated by subtracting the 
weight of the final construct from the weight of the materials used in the process. 
Equipment costs were determined as both initial sunk costs and costs of the 
consumables used in the process.  
Determination of Physical Parameters 
The extent of protein crosslinking and/or degradation was determined through 
the processing of proteins with excimer ablation. To provide a more rigorous test bed 
unmasked protein sheets were ablated with increasing number of passes from one to 
three. The films were then resolubilized in TFE and subsequently extracted in molecular 
grade water(MGW). The solution was centrifuged at 3000 rcf to pellet the protein which 
was then was resuspended in another 25mL of MGW and centrifuged again. This step 
was repeated one more time. The final pellet was resuspended in 10mL of MGW, frozen 
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at -80°C for 24 hours, and lyophilized for 72 hours . The samples were then run on SDS 
PAGE gels. In brief, Sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) analysis revealed protein bands at 250 kDa. A total of 40 g of elastin-mimetic 
proteins was run along with molecular weight markers (Precision Plus Protein 
Kaleidoscope, Bio-Rad) on a 7.5% gel and stained with Coomassie stain (Bio-Rad). 
To determine the sterility of material pre and post fabrication, lyophilized protein 
was resuspended in sterile MGW at 1 mg/mL, and endotoxin levels were assessed 
according to manufacturer instructions using the Limulus Amoebocyte Lysate (LAL) 
assay (Cambrex, East Rutherford, NJ).  
Tubular Construct Formation 
To fabricate the planar sheets into tubular constructs, the stents were hydrated 
and placed on a sheet of sterile aluminum foil. The aluminum foil was then wrapped 
around a mandrel 10% smaller than the final desired diameter. The stent was then 
allowed to dry for 24 hours under vacuum. The foil was removed, and the stent was 
taken off the rolling mandrel and placed on the attachment mandrel. The two abutting 
ends were either solvent welded or overlapped and solvent welded.  
Thin Walled Tube Formation 
The fabrication of thin walled tubes of elastin mimetic material was achieved 
through a dip coating procedure. Stainless steel mandrels were dipped into 100mg/ml 
LysB10 in TFE solutions. The mandrels were then inserted into a rotating chuck and 
rotated at 60 rpm. This allowed for a uniform distribution of the elastin mimetic material. 
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3.3 Results and Discussion 
The development of a fabrication process revolved around the ability to fabricate 
stents from an elastin mimetic material without damaging the material. The fabrication of 
stents from elastin mimetics required different fabrication processes than commercial 
stent manufacturing and experimental stent manufacturing as noted in Table 3.1. 
Processing conditions can severely alter the material properties of the elastin mimetic; 
therefore the first step in fabricating the stents was perfecting the ability to process the 
elastin mimetic materials which are concentration and solvent dependent. The solubility 
limit of elastin mimetic polymer in TFE was 200mg of protein in 1ml of solvent. TFE was 
chosen as a solvent because of its potential to provide an organic solvent that maintains 
the structure of the  protein[135, 136] and this allows for the formation of mechanically 
robust constructs[102]. Previous reports in our lab have shown that casting elastin 
mimetic materials from TFE can create stiffer films than those cast from water[102]. All 
of the fabrication techniques that were explored looked at the evaporation of solvent 
from the protein solution to create sheets or thin walled tubes. Thin walled tube 
fabrication was achieved through a simple dip coating process. The development of thin 
walled tubes allowed us to determine the initial mechanical properties of the elastin 
mimetic constructs and proved that solvent cast thin walled tubes have sufficient 
strength to perform stenting applications.  To allow the thin walled tubes to perform 
other stent functions fenestrations had to be added to them. Unfortunately none of our 
fabrication, techniques were able to create fenestrations in the thin walled tubing. 
Therefore, we explored the second major fabrication process which was planar sheet 
fabrication. This method allowed us to create two main stent designs, as noted in 
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Chapter 2. The first was the helical coil stent design that has been used by other 
research groups to explore novel stent materials[80, 89, 90]. This stent was easily 
fabricated by wrapping a thin film 4mm X 40mm to fabricate a stent with a 6mm inner 
diameter and a length of 10mm. The second design and the focus of the majority of this 
thesis was a generic design that is similar to the majority of commercial stents 
platforms. These stents were created from planar sheets with fenestrations formed into 
tubes. 
In order to create planar sheets with fenestrations, laser ablation and 
micromolding approaches were explored. These are two techniques that are used 
extensively in the MEMs field to create biomedical devices from biologically relevant 
polymers. The initial approach that was adopted for the fabrication of stents was a laser 
based technique that is similar to the procedures used to develop stents in the industrial 
settings. The initial limitations that made us pursue dual strategies were the process 
time, material waste, and potential contamination of the material. The second path that 
we pursued consisted of casting the elastin mimetic into PDMS molds to generate the 
desired stent design. This molding technique allowed for a high throughput process that 
minimized material waste.  
Excimer Laser 
The excimer laser was chosen because of its history of ablating biological 
materials with minimal thermal damage. Most traditional lasers often ablate materials 
with high temperatures which could denature or burn the elastin mimetics. The method 
of excimer ablation inputs highly focused UV energy into the material, thereby disrupting 
the molecular bonds which leads to material ablation.  Therefore, the elastin mimetics 
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should be able to be cut without changing the mechanical properties of the material that 
is left behind.   
To explore the potential of using the excimer laser to fabricate fenestrations in 
the protein sheets, a characterization protocol was used to determine the proper 
parameters that were needed. Figure 3.1 shows the ablation profiles when the number 
of pulses and the transmission are increased. The goal was to use the lowest fluency 
possible to ensure that the protein was not damaged. To determine the ablation depth 
for a given number of pulses and a given fluency, the protein sheets were examined 
under optical microscopy. The edges were also examined to ensure there was no edge 
damage or heat affected zone. Ultimately these tests proved that excimer laser ablation 
was feasible.   
First, we used a direct write method to fabricate a stent using the setup depicted 
in Figure 3.2 without a patterned mask. This process was capable of making 
fenestrations in the protein sheets, however, the time required to make a stent with this 
direct write method is not feasible (Table 3.2). Other limitations with this approach were 
material waste, laser consumable waste, and a lack of throughput.  
Table 3.2 The fabrication times for the different modalities are defined in terms of initial 
sunk time and time per stent. 
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The excimer laser schematic depicted in Figure 3.2 shows that two masks can be 
placed in the path of the laser. The first is an inline mask that allows the user to project 
that shape on the substrate to get ablated. Based on the output of the laser the largest 
opening in the mask can be 5mm x 5mm. Once the beam goes through the focus lens, 
the largest the beam can be in the direct write method is 1.25mm x 1.25mm. However, 
the size of the laser was not big enough to allow us to pattern a single stent cell. If this 
was the case the stents could be ablated one cell at a time which would drastically 
decrease the fabrication time. Therefore, we chose another way to decrease the cutting 
time is to use an in line pattern mask on the protein construct as shown in Figure 3.2.  
Excimer Laser with a Mask 
To overcome the time limitations of the direct write method, a masked laser 
ablation process was explored. Once the patterned mask was fabricated it was placed 
on top of solvent cast elastin mimetic sheets which allowed for the implementation of a 
high throughput way of making fenestrations. The masked approach allowed for the 
entire surface to be rastered, allowing us to employ a larger spot size and thereby 
reducing the time to5 minutes. To ensure complete ablation, six raster passes were 
used, and each alternating pass was offset by half the laser spot size to ensure even 
ablation. This method also allowed us to use a faster cutting time because of the 
simplicity of the laser movements. As shown in Table 3.2, the mask method allowed us 
to decrease the cutting time by 90%. This technique also performs well at these length 
scales. As the pattern becomes finer, more care must be taken to address potential 
shadowing and mask fidelity issues.  
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  While the masked laser approach offers the high throughput process, it still did 
not ameliorate the material waste and sterility concerns. Therefore, we sought a cheap 
high throughput fabrication process that would conserve our protein material and allow 
us to fabricate sterile constructs.  
PDMS Molding Technique 
The second fabrication technique that we explored was a PDMS molding 
technique commonly used in the MEMs field to fabricate 3D structures. The basic 
schematic can be seen in Figure 3.3. The fabrication of PDMS molds has more sunk 
time than the previous methods because of the time required to fabricate the reverse 
acrylic molds and PDMS molds. However, the PDMS molding strategy allowed for new 
stent designs to be tested in a day by providing a high throughput method, since several 
PDMS molds can be made simultaneously. The PDMS molding technique also 
minimized the amount of wasted protein polymer; therefore this process proved to be 
the most efficient method to fabricate, test, and analyze multiple designs. However, the 
biggest limitation of this modality is the design fidelity as noted in Table 3.2. This is 
caused by the biggest limitation of the molding process which was the formation of 
webbing.  
Casting Elastin Mimetics in PDMS Molds 
The casting solvent, TFE, has a low vapor pressure which caused the solution to 
evaporate quickly in the fume hood. When the solution evaporated too quickly stresses 
were formed in the polymer leading to nonhomogenous film thicknesses, wavy films, 
webbing on the intricate molds, and prevented casting a construct with multiple 
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layers[137]. To minimize and eliminate these limitations, the rate of vaporization was 
decreased by placing the molds in Petri dishes which were subsequently closed and 
sealed with parafilm. This setup created a TFE saturated environment which decreased 
the rate of solvent evaporation and increased the drying time of the constructs. The 
Petri dish was opened every twelve hours to release the vaporized TFE, a total of four 
times. In processes that require multiple coats, the casting conditions are followed 
again, and these steps can be repeated to get the desired thickness.  The raised 
portions of the PDMS mold were then wiped with a sterile cotton swab that had been 
dipped in TFE.  
Since this technique worked other variables were altered independently to 
evaluate their effect on casting. These alternatives consisted of: mold depth evaporation 
time solvent weight percent and cast number. It had been hypothesized that molds with 
deeper wells could be rinsed with solvent to eliminate webbing in the z direction as 
shown in Figure 3.4. However, this was not the case, and the films were ultimately 
unusable. In the end, the cleanest films were obtained by limiting the mold depth to the 
desired thickness of the constructs. Extended evaporation times did help the process by 
allowing for the formation of flat films which allowed for serial casting and minimized 
webbing. In our studies, the ability to change the weight percent was not beneficial. It 
was believed that increasing the concentration of the casting solution would allow us to 
cast the material without as much webbing. However, the 15% solution was overly 
viscous and did not pull into the molds properly, and therefore led to worse webbing the 
10% solution that was currently being employed. Finally, the serial casting strategy 
worked very well, and the subsequent cast layers solvated the previous layer well 
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enough to prevent any problems of creating a layered structure that ultimately could 
delaminate. With these changes in place we sought to explore the dimensional fidelity of 
the molding process. 
Examining the Design Parameters 
 To explore the quality and versatility of the fabrication process, the design fidelity 
was determined for stents with strut widths of 250µm, 500µm, and 750µm(Table 3.3). 
The cell areas, crown widths, and connector widths were measured at six points for 
each parameter to determine the design fidelity of the different processes. In order to 
determine the dimensional fidelity of our fabrication process, stent sheets were 
examined under optical microscopy, and the parameters of interest were determined 
and compared to our design number as shown in Table 3.3 When compared to the 
designed dimension, it was clear that the molding approach produced the constructs 
with the lowest design fidelity. The molding fidelity increased as the scale of the widths 
increased and these trends held for the other parameters as well(Table 3.3). Table 3.3 
also shows that the direct write fabrication method and masked projection methods are 
extremely accurate and created constructs that had close to the same width as the 
targeted design. The scale of the dimensions did not seem to affect the design fidelity of 
these processes. However, it should be noted that all three of the designs highlighted 
had feature sizes on the same order of magnitude. These results dictated that an 
optimized casting process had to be obtained to move forward with this fabrication 
modality. Since, the molding process offered many advantages, we explored the 
potential of optimizing the process to overcome its design fidelity limitations.  
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Table 3.3  Design Fidelity of Fabrication Processes  
Overcoming Molding Issues 
 The results from exploring design fidelity demonstrated that the widths of the 
struts and connectors were wider than anticipated. To ensure this was not caused by 
distortions or swelling of the mold, the mold was filled with TFE, allowed to incubate for 
48 hrs to represent the casting process, then the mold was measured. It was 
determined that the solvent does not swell the mold and dimensional instability was 
arising from webbing. The examination of the planar stent patterns illustrated two forms 
of webbing as shown in Figure 3.4 A. The first type of webbing occurs in the z plane and 
accumulates on the walls of the mold. The second type of webbing type happens in the 
xy plane and can cover the fenestrations in the mold.  
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Figure 3.4 PDMS molding was used to generate 3D structures from protein polymers. 
(A) The filling of a PDMS mold with protein polymers illustrated in webbing 
perpendicular to surface after one pour, webbing perpendicular to surface after three 
pours, an ideal case with no webbing and a filled well, and an overfilled mold with 
webbing parallel to the surface.  
The webbing in the z direction affected the thickness of the stents. As seen in 
Figure 3.4, the webbing can create thin portions of material that increase the overall 
thickness of the stent. Since one of the major design considerations was to minimize the 
overall stent thickness, this webbing must be eradicated. Any webbing in this direction 
will generate a weaker stent with regard to total thickness. A side profile showed that 
there is a base level of material, as well as webbing that was formed as the protein 
solution was evaporated in the mold. The initial experiments focused on making molds 
with deeper wells of 750µm. Once the film was cast, the thinner side wall webbing 
would be removed by adding excess TFE into the mold. When imaging the stents, it 
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was clear that the stents with the deeper wells had significantly more webbing even 
after the thorough washing steps. The interesting thing is that these peaks were higher 
with increasing well depth. However, the peaks were not as deep as the well. This 
observation showed that the side wall webbing was able to be reduced with washing but 
not eliminated. The next approach to minimize webbing in the z direction was the use of 
serial castings and shallower molds. This technique limited the webbing more than any 
other technique but it still left webbing that was not acceptable for the final stent design.  
The webbing in the xy plane affects the width of the struts and the area of the 
fenestration. While webbing in this direction can hurt the design fidelity, overall this 
webbing is easier to remove. The consensus from a fabrication point of view was to 
eliminate webbing in the z direction at the cost of having xy webbing. Therefore, we 
moved forward with overfilling the mold and creating webbing in the xy plane. Care was 
to taken to make the webbing in the xy plane as thin as possible so it would be easier to 
remove.  
Since webbing could not be completely eliminated by optimizing the molding 
conditions, a combinational approach was sought that would allow for forming the stent 
in the mold and a finishing step would be employed to eradicate the webbing in the xy 
plane. The strategies that were employed consisted of washing, cutting, reactive ion 
etching, and laser ablation.  The thinner the top film, the easier it was to remove that 
film with either of the processes listed above. The initial approach was to wash the 
surface of the mold after casting to eliminate the xy plane webbing. This works to a 
large extent but upon inspection there was still some residual webbing. Also the cast 
sheet can be removed from the mold if the washing is too aggressive. A cookie cutter 
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type device was fabricated that acted as a die and cut the stent; however, this had 
limitations regarding alignment and tearing the stent. Reactive ion etching was 
successfully used to selectively ablate the thinner protein based material; however this 
led to concerns that the chemically reactive plasma denatured the remaining material. 
The final approach was to use the excimer laser to ablate the webbing. We showed that 
the laser was able to ablate the webbing with and without a mask (Figure 3.5). We used 
a mask to prevent the laser from ablating the surface of the stent material. The reason 
that this method was effective was the thickness of the film was much less than the 
previous excimer attempts. 
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Figure 3.5 Samples A-F are 10X optical images (A) after over filled molding (B) and (C) 
after one and three rasterings respectively unprotected (D) after three rasterings with 
mask, (E) unmasked rastering three passes and (F) masked rastering after three 
passes.  
In conclusion, the molding process was optimized to allow for casting from low 
weight percent solution and generating minimal webbing. This webbing was 
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subsequently able to be removed with a finishing step. This method allowed for molding 
to successfully fabricate different stent designs in a high throughput process with 
minimal material waste.  
Determination of Protein Degradation and/or Crosslinking 
 The biggest concerns about using laser-based fabrication processes for 
biological materials are the incorporation of contaminants and the alteration of the 
biological material. In the molding studies, all components can be sterilized, and the 
casting can take place in a sterile hood with standard sterile technique. However, in the 
laser approach, contamination can come from the lack of sterility of the laser setup and 
the incorporation of radical particles during the fabrication process. There has been 
much thought into selecting processes that minimize the chance of contamination and 
denaturation. The utilization of the excimer laser to fabricate the final stent platforms 
required examination of the damage caused by thermal and UV exposure and potential 
crosslinking. To explore the effect on protein degradation, the proteins post fabrication 
were run on an SDS PAGE gel, and their percent extractables were calculated. In all of 
the stent designs that were fabricated we determined that there was no crosslinking as 
100% of the material was able to be extracted. Also, there appeared to be no 
generation of shorter protein sequences from the ablation, as the SDS PAGE gels had 
no unexplained protein bands. To further explore this we subjected the protein to 
unmasked rastering as noted in the methods sections.  
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Figure 3.6 (A) LysB10 film raster with excimer laser for 3passes 2 passes and 1 pass. 
(B) SDS Page gel of three samples a) LysB10 in water, b) lys B10 cast from TFE, c) 
laser ablated LysB10 (C) % extractables from laser ablated samples and control 
LysB10.  
  
Preventing Contamination  
A potential side effect of fabrication is the incorporation of endogenous and 
exogenous materials in the stent platform. In the laser process, the material that was 
ablated was redeposited on the surface. Based on the SEM evaluation, it appeared the 
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material redeposited on the surface could be removed by washing the sheet after 
ablation. The other point of emphasis was the ability to keep the material sterile 
throughout the process. However, the incorporation of the excimer laser prevented the 
process from being sterile throughout. Therefore, we needed to determine the sterility 
level of the protein sheets before and after fabrication to determine if the fabrication 
process was promoting the incorporation of endotoxins into the material. In order to 
explore the sterility of the different processes, the LAL assay was utilized. Levels of 0.1 
EU/mg were obtained (1 EU¼100 pg of endotoxin), which corresponds to endotoxin 
levels for clinically used alginate (Pronova sodium alginate, endotoxin_ 100 EU/g) It was 
determined that there was no statistical difference between the three different methods.  
Denaturation 
In a standard ablation process only the edge of the protein exposed to the UV 
and heat damage, and the edges tend to make up a small fraction of the entire material. 
Therefore, we believed that an effect of the UV laser on the protein sheet could be lost if 
we solubilized our patterns. Therefore, the denaturation and crosslinking experiment 
sought to make these effects more prominent by ablating the entire surface with multiple 
passes. In the current studies, it takes five passes with the laser to ablate the material 
completely and ensure there is no protein webbing left behind. We looked at protein 
sheets that were not covered with a mask and, instead, exposed them to direct ablation 
from the excimer laser. The fact that the stents completely went into solution shows that 
the crosslinking in not a problem(Figure 3.6).  
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Table 3.4 - Comparing the advantages and limitations of each approach 
Creating Stents from Planar Sheets 
 The chief drawback of the planar approach is the process required to form the 
stent from a planar sheet into a thin walled cylinder. The current procedure for attaching 
these stents begins by hydrating the patterned sheets for 1 hour in 37°C PBS which 
makes the material more pliable and allows for the material to be fixed in a shape when 
dried. Once hydrated, the stent was then placed onto sections of aluminum foil which 
allowed for easier handling of the stent and prevented the stent from tearing. The foil 
and patterned sheet were wrapped around a Teflon mandrel that is 10% smaller than 
the desired final inner diameter. The stent was then allowed to dry at room temperature 
for 24 hours. Once the stent dried, the aluminum foil was removed and the stent 
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conformed to the Teflon tubing. The next step was the attachment of the opposing sides 
of the sheet to make uniform cylinders, as shown in Figure 3.7. Several variables in the 
attachment process were explored, ranging from the type of solution used to attach the 
two sides and whether the ends should be attached by abutment or overlapped. 
Figure 3.7  (A) Planar Stent Sheet (B) Picture of planar and rolled stent (C) End profile 
of stent overlapping (D) End profile of stent  abutment attachment 
 The attachment solutions that were explored were TFE, 100mg/ml LysB10 in 
TFE and 200mg/ml LysB10 solution in TFE. The LysB10 solutions were syringed onto 
the abutting sides with 30 and 25½ gauge needles, respectively. The 20% solution was 
used because the 10% solution has such a low viscosity that it spread along the length 
of the attachment site. The TFE solution was syringed onto the attachment site with a 
30 gauge needle. The stent material was then brought in contact, and the adjoining 
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sides were solvent welded together. This solution worked best for solvent welding 
because the elastin mimetic solutions created webbing and exogenous material on the 
mandrel. 
 The attachment of the stents was the largest hurdle that had to be cleared to 
employ planar sheets in the fabrication of the stents. Two methods for attaching the 
stent were explored: the first was abutting the two sides of the stent, and the second 
was overlapping the film as depicted in Figure 3.7.
The ability to successfully fabricate stents form planar sheets was based on three 
endpoints; can the stent be successfully attached, removed from the forming mandrel, 
and created with no webbing. The favored attachment method from a design standpoint 
was to create stents by joining the two abutting sides. However, this method failed on all 
three of the criteria noted above. Firstly, it is difficult to bring the two abutting sides into 
contact and solvent weld them together. These connections were successfully formed in 
some cases, but there was a problem removing the stents from the mandrel as the 
attachment process allowed the stent to stick to the mandrel. This problem was 
exacerbated by the fact that the patterned sheets do not have much rigidity in the 
longitudinal direction and therefore if even one strut stick the stent will tear at that point 
yielding the stent useless. Therefore, the success rate for fabricating a stent with 
adjoining sides resulted in a success rate of less than 15%. The overlapping stents 
were able to be fabricated with a higher success rate. In the case of the overlapping 
stents attachment was facilitated by the fact that the wrapping allows the stent to have a 
fixed overlap so all that must be done is to tighten that overlap and add the attachment 
solution. Also since the attachment is mainly between the two ends the stent did not 
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stick to the mandrel with the same intensity as the previous attachment method. 
Therefore, the majority of the stents they were able to be removed from the mandrel. 
Once the stents were fabricated they were tested to ensure the quality of the 
attachment at the weld joint. The preliminary test of the attachment zone was to expand 
the stent. Initially the stents were imaged at the attachment zone to ensure the 
attachment was complete. The stents were than expanded to 1.1 times the fabricated 
diameter. Upon inflation the stents were examined to ensure that the welds at the 
attachment zone held. In many cases it was noted that the abutment attachment failed 
completely or in several points. This was attributed both to the contact area of the welds 
as well as reliability of the welds. In the overlapping case the amount of overlap was 
altered to increase the success of the stent. It was determined that in the 1.5mm stent 
design an overlap of 20% of the circumference or 942µm was sufficient.    
 The attachment of these stents is not ideal. However, the ability to overlap the 
stents provided a method to move forward and test the stents further. The ultimate goal 
is that a fabrication setup will allow us to fabricate these stents from thin walled tubes 
and ultimately eliminate the need to attach these stents.  
3.4 Conclusion 
Laser fabrication has proven a powerful tool for creating complex 3 dimensional 
structures out of biological material. The ability to use this fabrication method in tandem 
with PDMS molding allowed for a decrease in laser time while simultaneously 
minimizing the waste of these highly valuable materials. The ability to fabricate 
fenestrations in biological materials expands their applicability as smart mechanical 
design allows researchers another tool to recapitulate the native environment while 
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designing for a mechanical need. Fabricated films showed excellent fidelity and 
minimum laser issues. It has been shown with collaborators that this method builds the 
foundation of excimer ablation and allows for a process to fabricate constructs. In this 
regard, these methods have impact in a range of fields that are now turning to mimetic 
materials to improve efficacy and applicability. While specific applications for this 
technology are stated herein the potential to expand to other biomaterial applications 





Advancing the Biological and Physical Properties of the Elastin 
Mimetic Materials via Crosslinking, Drug Incorporation, and 
Enhancing Cell Binding 
4.1 Introduction 
The elastin mimetic stent platforms allow for the incorporation of additional 
factors that provide ways to augment their performance. In standard stent platforms, this 
is very challenging as seen by the laborious efforts to achieve stent coatings that have 
beneficial results without detrimental side effects[138]. The modifications of these 
elastin mimetics were explored on three fronts to combat the most common causes of 
stent failure.  The first was the crosslinking of the elastin mimetic stents to examine the 
effect it had on the biological, physical, and mechanical properties of the stent. We 
compared different crosslinkers and their effect on mechanical properties and drug 
retention time. We then examined the potential of incorporating pharmaceuticals and 
biopharmaceuticals into the stent platform. 
 The crosslinker selection was explored in such depth as the crosslinking agents 
were able affect all aspects of stent design, including the physical, mechanical, 
biological, and drug release properties. Preliminary studies have shown that vapor 
phase crosslinking of protein sheets provides robust mechanical properties and a 
reduction in the thickness of the crosslinked films compared to the uncrosslinked films.  
Genipin was the second crosslinker that was explored because of its known 
biocompatibility. Finally we will explore the potential of modifying the glutamic acid 
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residues in the elastin mimetic sequence with a cystamine residue that can be reduced 
and then oxidized to form disulfide crosslinks. 
 The physical properties of the elastin mimetic materials were observed to 
determine the effect of crosslinking on these materials. Effects of particular interest for 
this research included the thickness, swelling ratio and water content of the constructs 
upon hydration. The potential to modulate the mechanical properties of these materials 
was explored to tailor the stent designs and to use different designs based on the 
achievable strength. The ability to incorporate drugs and tailor the drug elution 
properties was investigated for their potential to successfully combat the smooth muscle 
cell overproliferation event. As a corollary, the potential to enhance the 
endothelialization of the stent constructs was examined as endothelialization is of 
paramount importance to combat late stage thrombosis. This can be achieved by 
enhancing the healing ability of the stent through pharmacologically promoting, as well 
as physically trapping circulating endothelial progenitor cells. Finally, the 
biocompatibility of the different crosslinkers was explored. Crosslinking and modulating 
these biomaterials must not come at the expense of the biocompatibility of the material. 
While glutaraldehyde is a well documented effective crosslinker, its lack of 
biocompatibility has decreased its utility. Therefore, other biocompatible agents such as 
genipin have become more common.  
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4.2 Materials and Methods 
Production and Fabrication of TFE Films  
The  recombinant elastin mimetic polymer, LysB10, studied in this report has 
been described elsewhere[87]. Briefly, the elastin mimetic material is composed of a 58 
kDa hydrophilic central midblock composed of 28 repeats of the elastic sequence 
[(VPGAG)2VPGEG(VPGAG)2] flanked by 75kDa hydrophobic  endblocks composed of 
33  repeats of the pentapeptide sequence[IPAVG]5. To allow for enhanced crosslinking 
the residues [KAAK] were located at the C terminus and between the midblock and 
endblock.  
These proteins were further modified to allow for sulfide crosslinking. The LysB10 
was dissolved in phosphate buffered saline(PBS) with a 20-fold molar excess of 
cystamine and 5-fold molar excess of N-(3-dimethylaminopropyl)-N‘-ethylcarbodiimide 
(EDC). These were allowed to react for 72 hours at 4ºC. The elastin mimetic was then 
purified with dialysis. When necessary, the cystamine group was reduced with (tris(2-
carboxyethyl)phosphine(TCEP) to form thiols. 
For all of the analysis, films were solvent cast from 100mg/mL lyophilized protein 
dissolved in 1mL 2,2,2-Trifluoroethanol(TFE). The solution was solvent cast in Teflon 
molds, yielding films with a thickness of approximately 100µm ± 12µm. The films were 
then placed on a sterile glass grid and diced into the desired dimensions. The samples 
were then weighed to ensure that any change in size was accounted for; the average 




Cast films were crosslinked via one of the following crosslinking methods. 
Glutaraldehyde vapor phase crosslinking was achieved by placing the films on a glass 
plate suspended above a reservoir of 25% (w/v) solution of glutaraldehyde (GTA) 
(Sigma Aldrich, St. Louis, MO) in water in a closed chamber and then vapor crosslinked 
for 48 hours. The thiol air oxidation setup consisted of leaving the film in a Petri dish for 
a period of 5 days. The films were then removed, vacuum dried for 48 hours, and then 
rinsed.  
Solution phase glutaraldehyde crosslinking was completed using 0.5% 
glutaraldehyde. The solution was made from 25% glutaraldehyde and molecular grade 
water. The films were immersed in the solution phase GTA for 24 hours. Genipin 
crosslinking was completed by solubilizing 6mg/ml Genipin into phosphate buffered 
saline (PBS). The solution was allowed to crosslink for 24 hours. The solution phase 
thiol crosslinking was accomplished by reducing the cystamine groups with TCEP for six 
hours. The films were then placed in 0.1% H2O2 solution made from 30% sodium 
hydroxide(Sigma Aldrich) and PBS. The pH of the solution was raised to 7.3 using 
sodium hydroxide.  
Confined crosslinking was achieved through the device shown in Figure 4.1. The 
device consists of two glass slides(2.5mmx7.5mmx1mm) and  filter paper(Millipore) 
placed on the top and the bottom of the protein film. Two U shaped plastic connectors 
were compression fit over the setup to minimize swelling. The confined system was 
placed in a Petri dish filled with the applicable solution phase crosslinkers.  
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Figure 4.1 Confined crosslinking setup 
To remove unbound crosslinker, a rinsing procedure was utilized after all 
crosslinking procedures to remove any residual crosslinker. It consisted of 5 exchanges 
of PBS over a 48 hour period.  
Evaluation of Physical Properties 
The surface area, thickness, and weight of the films were measured in the dried 
and hydrated state after crosslinking. The films were imaged under 4x and 10x 
magnification to determine their surface area and thickness. The weight of the films was 
obtained on a mechanical balance (Mettler-Toledo, Columbus, OH). The thickness ratio, 
equilibrium water content, and equilibrium swelling ratio were determined according to 
Equations 1, 2, and 3, respectively, and were expressed as mean ± standard deviation. 









THAC  Hydrated thickness after crosslinking 
TBC  Dried thickness before crosslinking  













WH  Hydrated Weight  
WD  Dry Weight  
2.4 Evaluation of Degree of Crosslinking 
The amount of extractable protein was obtained by placing the cast protein films 
into 1mL of the casting solvent for seven days at 37°C. The films were removed from 
the TFE solution, placed in a vacuum chamber for 72 hours to remove any residual 
TFE, and then weighed. Six protein strips were tested for each experimental group. The 
percent of extractable protein was determined using Equation 4 and expressed as a 












WD  Dry Weight  
WE  Weight After Extraction  
The extent of crosslinking site utilization was determined using the ninhydrin 
assay for lysine residues and Ellman’s reagent for thiol groups. The extent of 
crosslinking was calculated using Equation 5 and expressed as a mean ± standard 
deviation. Six protein strips were tested for each experimental group.   
Equation 5. 
  
Xu  Free sites in uncrosslinked samples  
XC  Free sites in crosslinked samples 
To determine the quantity of amino groups that were not crosslinked the 
ninhydrin assay was used[139]. The elastin mimetic samples were weighed and heated 
with a ninhydrin solution for 20 minutes. Then the solution was allowed to cool to room 
temperature and diluted in 95% ethanol. The optical absorbance of the solution was 
quantified with UV–visible spectrophotometer (Cary 50; Varian Inc., Palo Alto, CA) at 
570 nm using glycine at various known concentrations as a standard curve. Six protein 
strips were tested for each experimental group.   
Ellman’s reagent was utilized to quantify the extent of thiol modification of the 
elastin mimetic. A cysteine standard curve was generated with 0 to 1.5 mM cysteine 
dilutions in a reaction buffer of 0.1 M sodium phosphate with 1 mM EDTA, pH 8.0. 











reaction buffer. Reduced 10 mg/mL elastin mimetic-cystamine solutions and the 
surfaces of a 10wt% hydrogel were reacted with Ellman‘s Reagent solution diluted in 
reaction buffer and incubated at room temperature for 15 minutes. Absorbance at 412 
nm was quantified with UV–visible spectrophotometer (Cary 50; Varian Inc., Palo Alto, 
CA). Values were compared to a standard curve to obtain the experimental sample 
concentrations.  
Mechanical Analysis of Hydrated Films 
Uniaxial stress strain tests were performed on the different crosslinked films. The 
test consisted of a preconditioning protocol that consisted of 10 cycles of 10% strain 
with offloading periods of 5 minutes between each cycle; preconditioned samples were 
then tested until failure. The instrument used was a dynamic thermal analyzer( DMTA V, 
Rheometric Scientific, Inc. Newcastle, DE) with a 15-N load cell in the inverted 
orientation to allow samples to be immersed in a jacketed beaker with 37°C PBS. The 
tensile tests were used to calculate the elastic modulus, strain at failure, and ultimate 
tensile strength. The elastic moduli for the confined and unconfined films were taken at 
two linear regions, 5%-15% strain and 50%-175%, occurring before and after the yield 
point. Since the maximum travel distance of the DMTA is 23mm some of the more 
extensible materials had to be moved to be tested to failure on the miniature materials 
tester (Minimat 2000, Rheometric Scientific) in tensile deformation mode at a rate of 5 
mm/min conducted in air at room temperature. All samples were coated with a thin layer 
of mineral oil to prevent dehydration. For both DMTA and Minimat testing, samples were 
cut into a dumbbell shape using a stainless steel die with gauge dimensions of 13 mm x 




 The model system used to explore the drug elution of these materials was based 
on a ring from the current stent design. The surface area of the current three ring stent 
prototype has a surface area of 157.78mm2 and contains a drug volume of 220µg. This 
yields a surface area drug concentration of 1.39µg/mm2. The model system has an area 
of 28.27mm2 and requires 39µg of drug. The samples were cast in a 30x24mm mold 
and resulted in a film thickness of approximately 100µm ± 12µm. The films were then 
cut with a razor blade into the six equal strips that approximate the drug eluting ring. 
This is accomplished by placing the sample on a sterile glass sheet that is placed onto a 
grid structure that facilitates accurate cutting of the samples. The samples are then 
weighed to ensure that any change in size was accounted for; the average weight of the 
films is 8mg ± 1.7mg. The constructs were placed in centrifuge tubes containing 2mL of 
release medium and placed on a shaker rotating at 500rpm at 37°C. The release 
mediums used were 90:10 PBS and Ethanol at 37ºC[80]. To ensure that the release 
mediums were not significantly altering the constructs their thicknesses and weights 
were recorded. Samples of the release medium were removed at 2 hours, and 24hours 
and every subsequent day until the drug release was no longer quantifiable. All of the 
elution profiles were determined with UV spec and a standard curve ranging from 
0.5µg/ml to 150µg/ml. 
 There were three drug incorporation strategies that were utilized. The first 
consisted of two depositions of 333µl of 100mg/ml LysB10 protein TFE solution and a 
top coat of 333ul of 100mg/ml LysB10 in TFE with 1mg of drug.  The second strategy 
consisted of three casts of 333µl of 100mg/ml LysB10 in TFE with 333µg of the drug.  
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The third strategy consisted of one layer cast from 333µl of 100mg/ml LysB10 in TFE, a 
second layer of 333µl of 100mg/ml LysB10 with 1mg of drug, and a third layer of 333µl 
of 100mg/ml LysB10 in TFE. The effect of crosslinking was determined on the stent with 
drug throughout the stent. The films were crosslinked as previously described. The 
samples were removed and placed in sterile PBS, and this process is repeated for a 
total of 8 washes.  Because some of the drug could elute during the process, a drug 
retention quantity will be calculated as seen in Equation 6.  






In all of the cell experiments, 75µl of 10% elastin mimetic were cast into wells of 
a 96 well plate and allowed to evaporate over 48 hours with the lid on and subsequently 
placed in a vacuum for 120 hours. The films were then subjected to their respective 
solution phase crosslinking procedures. All samples, including the control films, were 
washed 10 times over the course of 48 hours at room temperature. The samples then 
had 50 µl of 250ug/mL solution of Fn adsorbed to the surface for 24 hours. The samples 
were then washed once with PBS and cells were seeded. Since the assay used was a 
terminal assay, the 2 hour and 48 hour plates were discrete but were prepared at the 
same time from the same solutions. 
All of these studies used human umbilical vein endothelial cells (HUVECs) 
(Clonetics). Prior to use, HUVECs were cultured in a t75 flask with endothelial growth 
medium-2 (EGM-2, 2% serum, Clonetics) and were kept in a humidified, 5% CO2
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environment at 37°C. The cells were passaged, upon confluence, using standard 
culture techniques. All cells used in the study were between passages 4 and 9.  
 For the adhesion assay, HUVEC suspensions were prepared at a density of 
200,000 cells/mL, and for the proliferation assay the density was decreased to 50,000 
cells/mL. The samples were seeded with 100µL of the cell suspension. The plates were 
then incubated for 2 hours at 37°C. To determine ad hesion, after 2 hours the wells were 
washed three times with PBS. The plates were then placed in the -80°C freezer for 24 
hours. To explore cell proliferation on these materials, the cells were seeded as 
discussed above. At two hours the surfaces were rinsed with 100µl of media three times 
to remove unbound or loosely adhered cells. The bound cells were cultured for a total of 
48 hours in 100µl of media
Cell adhesion and proliferation was determined with the CyQuant Cell 
Proliferation Assay Kit (Molecular Probes). Briefly, after thawing frozen cells to enhance 
lysis, the CyQuant cell lysis buffer was added to each sample, along with CyQuant 
fluorescence reagent. Samples were then measured in a microplate spectrofluorometer. 
A standard curve ranging from 50,000 to 100 cells was created for each sample set. 
Statistical Analysis  
Comparison between groups was analyzed via ANOVA and a paired, two-tailed 
student‘s t-test, with p<0.05 considered to be significant. Results are presented as 




Results Physical Properties 
 The physical properties of the elastin mimetic materials were modulated by the 
crosslinker used. The thickness ratio, swelling ratio, and water content were the 
physical properties that were explored. Changes in the area of the film were also 
measured in the x and y direction but there was no significant difference in any of the 
films. The following results demonstrate an ability to modulate the physical properties of 
the stent by careful selection of both crosslinking agent and crosslinking setup. 
Thickness: There were two major trends in the crosslinking thickness 
data(Figure 4.1A). First the vapor phase crosslinkers produced the films with the lowest 
swelling ratios. Second the ability to confine the films when using solution phase 
crosslinkers allowed for a reduction in the thickness ratio. The thickness of the 
noncrosslinked elastin mimetic films had a swelling ratio of 44%. The genipin was 
slightly less at 36%. The confined crosslinking setup was able to significantly reduce the 
thickness ratio to 14%. In the glutaraldehyde system, the unconfined samples had the 
highest swelling ratio although it was not significantly higher than the controls. The 
confined crosslinking reduced the swelling ratio to 25% and that was further reduced to 
6% by the vapor phase crosslinking method. In the thiol based systems, the thickness 
ratios of the unconfined samples were slightly lower than the controls at 38%. The 
confined crosslinking thickness ratio was significantly lower at 21%, and the vapor 
phase crosslinking method yielded an ever lower ratio of 7%.  
Water Content: In the water content studies, both the solution phase 
crosslinkers and the confined crosslinkers were not significantly different from the 
controls. However, the confined samples had a significantly lower water content 
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compared to the unconfined crosslinking samples. The water content of the two vapor 
phase crosslinkers was significantly less than all other groups, but they were not 
significantly different from each other. On average the confined crosslinked films had 
19.3% less water than the solution phase crosslinkers and the vapor phase crosslinked 
constructs had 30.4% less water than the solution phase unconfined samples. 
Swelling Ratio: The swelling ratios for the solution phase crosslinkers were 
higher than the controls; however, the difference was not significant. The swelling ratios 
between the solution phase unconfined crosslinked constructs and the solution phase 
confined crosslinkers were significantly different in all crosslinking groups. The 
crosslinking modality with the largest difference was the glutaraldehyde samples. The 
vapor phase crosslinked constructs were significantly different from the unconfined 
crosslinked samples but were not significantly different than the confined crosslinking 
setup. Compared to the unconfined crosslinking, the confined crosslinking and vapor 




Figure 4.2.  (A) Thickness ratio of the different crosslinked samples, (B) Water content 
of the various crosslinked films, and (C) The swelling ratio of the different crosslinked 
samples. The unconfined samples are shown in black the confined are light gray and 
the vapor are dark gray.  
Results Mechanical Analysis 
 Samples were preconditioned and then strained until failure. All of the hydrated 
films possessed plastic-like deformation, consisting of a linear stress strain relationship, 
until a yield point and then another linear stress strain relationship until failure. The four 
parts analyzed were the elastic modulus from 5-15% strain and 40-175% strain, ultimate 
tensile strength, and the strain at failure(Figure 4.3).  
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The stress strain plots of the control and crosslinked samples all have two linear 
stress strain curves from 5 -15% and 40-175%(Figure 4.3). On the stress strain plots, 
there is a region from 0-3% that shows some minor plastic deformation occurring during 
the preconditioning step. The plastic deformation region is larger on the crosslinked 
samples then the control samples. 
The moduli for 5-15% strain in the control samples were not significantly 
different. However, they were significantly different than all crosslinked samples. The 
materials with the highest modulus in this range were the GTA samples, and the vapor 
and confined crosslinking thiol samples which were significantly different than the other 
crosslinking methods. In the higher 40-175% strain zone, the uncrosslinked samples 
were significantly different from all other materials tested. The stiffest sample in this 
range was the vapor phase crosslinked sample. The genipin samples wee also the least 
stiff of the crosslinked samples. 
 The confined crosslinking setup produces stiffer materials than the solution 
phase crosslinking setup. In the case of genipin, confined crosslinking increased the 
modulus by 46% in the 5-15% range and was not statistically different in the 40-175% 
range. The glutaraldehyde samples had a higher modulus than all respective groups. 
The other trend worth noting is that the values from the confined samples were higher 
than those of the unconfined samples. These values are 1.5 to 3.5-fold greater than 
those calculated for the uncrosslinked control.  
 The 5-15% modulus of the control confined and unconfined samples were almost 
identical at 0.20MPA. The glutaraldehyde confined and vapor phase crosslinking setups 
had the highest average moduli at 0.73MPa and 0.69MPa, respectively. The genipin 
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crosslinked samples had the lowest modulus values but were still more than 50% higher 
than the control uncrosslinked samples. The thiol crosslinking also showed a high 
modulus especially for the vapor phase and confined samples.  
 The second modulus is two orders of magnitude smaller than the first for both 
control samples and genipin crosslinked samples. The vapor phase glutaraldehyde and 
thiol crosslinking strategies have significantly higher moduli from 40%-175% strain. In 
both the genipin and thiol samples, the solution phase unconfined was significantly 
lower than the solution phase confined crosslinking setup.   
 The slope of the second modulus is much less steep than the modulus in the 5-
15% range. In the control samples, modulus 1 is 52 times greater than modulus two. 
The solution phase glutaraldehyde samples and the genipin unconfined solution phase 
crosslinker samples all have a second modulus that is approximately 60 times smaller 
than the modulus between 5-15%. The thiol vapor had the smallest ratio of modulus 1 to 
modulus two with modulus 1 being 34 times greater than modulus 2.  
The strain at failure of the control samples was significantly higher than any of 
the crosslinked samples. Also the strain to failure of the solution phase unconfined 
glutaraldehyde and thiol samples were significantly higher than the vapor phase 
crosslinking samples. The glutaraldehyde confined crosslink samples were significantly 
different than the solution phase crosslinker.  
Overall the ultimate tensile strength of the material can be increased by 42% for 
solution phase genipin up to 107% for vapor phase glutaraldehyde over the control 
samples. In both the thiol and vapor crosslinking samples, the vapor phase and 
unconfined solution phase crosslinking setups were significantly different.  In all three 
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setups the confined crosslinking tended to produce a higher UTS although it was not 
significant.   
Figure 4.3. Stress strain plots for (A) control constructs, (B) genipin crosslinked 




Table 4.1 Compiled mechanical parameters of noncrosslinked and crosslinked protein 
films 
Results Determination of Degree of Crosslinking 
The degree and type of crosslinking was calculated using percent extractables as 
a measure of crosslinking between chains and degree of crosslinking as a measure of 
interaction among crosslinking sites(Table 4.2). To explore the percent extractables, the 
samples were placed in their casting solution and the percent incapable of being 
resolubilized was determined. Noncrosslinked films placed in the casting solvent 
dissolved instantaneously, resulting in 100% extractables. The next highest was the 
thiol vapor phase crosslinker at 16.62 ± 1.96%. It should be noted that the thiol solution 
phase crosslinked sample had much lower percent extractables, 6.81±1.28%. The 
genipin confined had the third highest percent extractables at 11.74± 2.5% which was 
significantly higher than the solution phase genipin crosslinking. The glutaraldehyde 
101 

vapor phase samples had the highest percent extractable and the solution phase 
unconfined had lower percent extractable values; however the differences were not 
significantly different. The values for percent extractables are good agreement with 
previously published values[85].  
Table 4.2 Shows the percent extractables of the different crosslinking methods and 
shows the degree of crosslinking group interaction.  
 The degree of crosslinking in the elastin mimetic materials was determined 
quantitatively with ninhydrin and Elleman’s reagent. The GTA and genipin crosslinking 
strategies rely on lysine residues to form their crosslinks, and the thiol based 
crosslinking system utilizes modified carboxyl groups. The elastin mimetic films contain 
8 lysine residues per repeat and 28 glutamic acid residues per repeat. The thiol 
modification procedure was able to modify 64±3.5% of the glutamic residues resulting in 
17 or 18 crosslinking sites per repeat. The confined crosslinking setups had a 
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significantly lower degree of crosslinking compared to the unconfined except for the 
glutaraldehyde. The vapor phase thiol crosslinking system had the lowest degree of 
crosslinking at 66.29±2.59 compared to the two solution phase crosslinking setups 
which had degrees of crosslinking that were more than 30% higher than the vapor 
phase. In the glutaraldehyde samples, the vapor phase has the highest degree of 
crosslinking followed by the confined solution.  
Results Drug Elution 
To determine the drug elution of the protein materials, a model system was used. 
To ensure that this release medium did not change the physical properties, the material 
thickness and swelling ratio were noted. There was no significant difference between 
the samples placed in PBS and release medium. The different drug layering and 
crosslinking techniques were used to see if the drug elution could be tailored.  
The first scheme consisted of two layers of elastin mimetic with no drug and a top 
layer of elastin mimetic with 3.3% rapamycin. The second scheme had the drug mixed 
in the protein solution and was cast in triplicate. The third sample scheme consisted of a 
base coat of elastin mimetic with no drug followed by a layer of elastin mimetic with 
3.3% drug followed by a top layer of drug free elastin mimetic. Figure 4.4A shows that 
scheme one has the highest initial burst and an overall faster drug release profile, and 
scheme three gives the lowest burst and overall slowest drug release. The burst release 
was 17.91±1.71µg for scheme one, 13.98±1.26 µg for scheme two and 9.55±1.24 µg for 
scheme three. Interestingly, the release rate for scheme two was the fastest. Also worth 
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noting was the release of 50% of the drug quantity was delayed from half a day to one 
day by placing the drug in the middle of the stent instead of throughout the matrix.  
 The second round of experiments looked at the effect crosslinking would have on 
the drug delivery kinetics. The drug was distributed throughout the material as 
described for scheme two. Glutaraldehyde was able to significantly reduce both the 
burst release and increase the delivery duration. The vapor phase crosslinking was able 
to retard the drug delivery the most followed by the confined crosslinking. The solution 
phase unconfined sample had a faster release then the other two (Figure 4.4B). 
Solution phase genipin crosslinking was able to slow the drug elution profile compared 
to the control. Also confined crosslinking further suppressed the drug delivery curve 
(Figure 4.4C). The thiol crosslinking strategy showed the same potential to slow drug 
delivery. The thiol vapor crosslinking was able to retard the drug elution the best 
followed by the confined and then the unconfined (Figure 4.4D). The crosslinking 
studies showed that vapor phase crosslinking materials allows for the slowest drug 
elution profiles with vapor phase glutaraldehyde and vapor phase thiol having the lowest 
initial burst (1.44±0.07µg and 2.08±0.78µg) respectively. The confined crosslinking also 
showed potential to decrease the burst profile and slow the drug release profiles. 
Finally, it should be noted that crosslinking alone was capable of reducing the initial 
burst from 13.98±1.26µg to 1.77±1.71µg for glutaraldehyde, 4.55±0.69 µg for genipin, 
and  9.43±0.93µg for thiol.  
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Figure 4.4 (A) Illustrates the elution profile of LysB10 and three types of drug 
distribution. (B) Depicts the difference between different genipin crosslinking conditions, 
(C) Shows affect of different GTA crosslinking methods, and (D) Shows the difference 
between thiol crosslinking methods  
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Table 4.3 Drug Elution Parameters  
Results Endothelialization 
The adhesion and proliferation of endothelial cells on the various crosslinked 
surfaces was explored. Images of the cellularized surfaces were taken at 2 and 48 
hours to observe both cellular morphology and qualitative cellular properties of the 
material(Figure 4.5). The elastin mimetic film with no Fn adsorbed had notably fewer 
cells and the morphology of the cells was rounded and not spread out(Figure 4.5A and 
B). The elastin mimetic with Fn adsorbed showed that the Fn aided in cell adhesion and 
spreading on the elastin mimetic material. However, there are visibly less cells on this 
material than the crosslinked materials (Figure 4.5C and D). The genipin crosslinked 
films with adsorbed Fn showed good morphology, a high cell number, and a large 
increase in cell number(Figure 4.5E and F). The glutaraldehyde crosslinked films with 
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adsorbed Fn showed good morphology and cell number; however, the cell number on 
the 48 hour samples did not show good proliferation(Figure4.5G and H). The thiol 
crosslinked material seemed to perform best in both adhesion and proliferation(Figure 
4.5I and J).The final set of pictures is of the control wells which had Fn adsorbed to non 
tissue culture polystyrene at 2 and 48 hours, respectively. In all of the crosslinked 
samples with adsorbed Fn, HUVECs were capable of adhering and spreading. These 
images give a qualitative value of cell adhesion and proliferation on the different 
surfaces. To achieve a quantitative value of cell adhesion and spreading, a CyQuant 
assay was used.  
The first parameter that was explored was cell adhesion. The control elastin 
mimetic with no adsorbed Fn had the lowest cell adhesion and the Fn on non tissue 
culture treated polystyrene yielded the highest adhesion value. The elastin mimetic film 
without adsorbed Fn had a cell adhesion equivalent to 20% of the value for the Fn 
adsorbed control well. This value is half that of the elastin mimetic well that had 
adsorbed Fn. The fact that adsorbing Fn causes a 2 fold increase in cell binding is a 
significant finding. The crosslinked samples performed better than the non crosslinked 
samples. The genipin crosslinked samples performed best with an adhesion rate of over 
89% that of the Fn control. The thiol was close at 70% and the glutaraldehyde was the 
least effective of the crosslinked samples.  
To explore the proliferation rates of HUVECs seeded on different surfaces, the 
cell number was measured at 2 hours and 48 hours. As mentioned in the methods 
these studies had a lower cell seeding density to allow for proliferation without 
overcrowding. The uncrosslinked elastin mimetic without Fn does not promote cell 
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adhesion nor cell proliferation. In all of the other samples, the HUVECs were capable of 
adhering, spreading, and proliferating. It should be noted that at the 2 hour time point 
the trends are the same as those of the adhesion assay even with the decreased cell 
seeding number. As with the earlier adhesion studies, the poorest and best performers 
of the Fn treated samples are the uncrosslinked elastin mimetic and the polystyrene, 
respectively. A fold increase in proliferation was determined by dividing the 48 hour time 
point by the 2 hour time point. The genipin sample had a 5.37±.26 fold increase, the 
thiol surface had a 4.64±0.39, and the Fn on PS produced a 4.92±.47 fold increase. 
These were all significantly higher than the other samples, but not significantly different 
from each other. The elastin mimetic Fn control had a significantly higher fold increase 
then GTA at 3.93±.34 compared to 3.31±.21. The cells were not able to proliferate well 
on the elastin mimetic surface with no Fn adsorbed with a 1.44±.67 fold increase. Figure 
4.6A and B are the average of four separate experiments consisting of 6 wells for each 
group.   
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Figure 4.5. Optical images of LysB10 solvent cast films seeded with cells at 2 and 48 
hours. Images A and B are for Lys B10 with no Fn adsorbed at 2 and 48 hours 
respectively. Images C and D are for Lys B10 with Fn adsorbed at 2 and 48 hours 
respectively.  Images E and F are for Lys B10 with Fn adsorbed after a genipin 
crosslinking step. at 2 and 48 hours respectively. Images G and H are for Lys B10 with 
Fn adsorbed after a glutaraldehyde crosslinking step at 2 and 48 hours respectively. 
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Images I and J are for Fn adsorption onto thiol modified Lys B10 crosslinked via 
disulfides crosslinking step at 2 and 48 hours respectively. Images K and L are for Fn 
adsorbed non tissue culture PS at 2 and 48 hours respectively 
Figure 4.6 (A) Shows the cell adhesion on the different crosslinked surfaces with Fn 
adsorbed. In this panel all cell numbers have been normalized to the Fn surface. (B) 
Shows the adhesion and proliferation on the different crosslinked surfaces. 
4.4 Discussion  
Crosslinkers are a valuable tool to modulate the physical properties of elastin 
mimetic materials. The initial mechanical testing experiments discussed in Chapter 2 
showed that the vapor phase glutaraldehyde crosslinking system provided the 
necessary mechanical and physical properties for stent development. However, 
glutaraldehyde does not provide the needed biological properties as it has been linked 
to inflammation and cytotoxicity. Glutaraldehyde is still used because of its widespread 
availability and its crosslinking properties are well characterized. However, as the 
biocompatibility data continues to support the need for implementation of other 
crosslinking setups, glutaraldehyde will continue to lose favor as an acceptable 
110 

crosslinking modality. To this end, we explored a biocompatible lysine crosslinking 
strategy and a glutamic acid residue modification followed by disulfide crosslinking.  The 
first crosslinking strategy consisted of solution phase genipin crosslinking which is able 
to crosslink primary amine groups[140]. The second crosslinking method involved 
further modification of the protein backbone to allow for thiol based crosslinking. An 
advantage of this thiol crosslinking is that it can take place in the air or, for a higher 
crosslinking density, constructs can be placed in mild hydrogen peroxide solutions.  
The majority of crosslinking agents are solution based and the few vapor based 
crosslinking strategies are limited to toxic chemical based crosslinkers. Therefore, we 
attempted to achieve physical properties similar to the vapor phase crosslinkers by 
confining the solution phase crosslinking process. This process was demonstrated and 
allowed us to obtain crosslinked films with properties closer to the vapor phase 
crosslinked constructs.   
Physical Properties 
There are a range of physical properties that could be examined with regard to 
crosslinking performance. The physical properties that we explored were selected 
based on the end goal of using these materials in stenting applications. The first was 
the thickness ratio, which is useful in ultimate translation into stent design. The ability to 
minimize the thickness of the material construct allows for the stents to have a higher 
material percent allowing for the fabrication of more robust stents. The other two 
physical properties that were explored were the swelling ratio and water content. These 
parameters were benchmarked, as they translate into the degree of crosslinking, and 
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allowed us to compare and contrast crosslinking strategies. These properties play a 
large role in the drug delivery potential of the material. 
The goal of this work was to minimize the increase in thickness ratio by looking at 
a range of crosslinking modalities. Overall the solution phase crosslinkers were not able 
to decrease the thickness ratio compared to the controls and actually the solution phase 
glutaraldehyde samples had higher ratios; although they were not significant. The vapor 
phase and confined crosslinking setups were able to decrease the swelling ratio 
compared to the control constructs.  
It was also noticed that the solution phase crosslinking of the constructs had a 
higher thickness ratio than the vapor phase. When these parameters were further 
explored, it was determined that the thickness ratio of the vapor phase constructs could 
be misleading. As shown in Figure 4.2A, the thickness ratio of the vapor phase 
crosslinked construct increased by 7.3%. However, this was determined by measuring 
the dried film pre-crosslinking and the hydrated film post-crosslinking. In the case of the 
vapor phase crosslinking, the thickness of the construct decreased once it was 
crosslinked by almost 10% which means that it has an actual ratio of 18.88% which was 
close to the confined solution phase crosslinker value of 25.83%. The same process 
occurs for the thiol vapor crosslinking setup. The confined control shows that the 
confinement itself does not alter the thickness ratio of the construct. The confinement in 
the other three cases was able to decrease the thickness. 
The confined setup seems to produce a very real effect with regard to the 
thickness ratio, swelling ratio, and water content. The initial thought was that the 
swelling of the construct occured on a shorter time scale than the crosslinking[141]. It 
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was hypothesized that confinement limited the swelling of the film, but still allowed the 
solution phase crosslinker to diffuse in and out of the construct, thereby decreasing the 
physical parameters discussed above. Overall our unconfined results correlate with 
another study on genipin and glutaraldehyde crosslinking [142]. 
Mechanical Analysis 
 The mechanical behavior of the constructs was studied through stress strain 
curves obtained from stress strain tests. The samples were preconditioned to allow the 
microstructure of the constituent polymer chains to obtain a fixed structural relationship 
allowing for repeatable material properties[143, 144]. Previous characterization of 
LysB10 under different casting conditions used preconditioning loops of an initial 50% 
strain followed by 19 loops at 20% strain. That was not possible with these films due to 
the amount of plastic deformation that was not recoverable, therefore, the constructs 
were strained to 10% for 20 cycles. Also the calculated stress was based on the force 
obtained from the DMTA and divided by the cross sectional area of the sample. Since 
the samples had different physical properties, the cross sectional areas were calculated 
accordingly. The characteristic curve for these materials has a higher modulus at lower 
strains, 5%-15% strain, then a yield point, which is followed by a lower modulus until 
failure. This has been seen in native pig elastin by other researchers[145].  
TFE is capable of solvating both the hydrophilic and hydrophobic blocks of this 
elastin mimetic material which yields a film with interpenetrated blocks upon solvent 
evaporation. When these constructs are rehydrated, there could be some phase 
separation and block aggregation. However, some of these portions will remain 
kinetically trapped. This interphase mixing of incompatible endblocks allow these 
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materials to have tensile properties that resemble those of polystyrene[102]. This effect 
can be more dramatic in the vapor phase crosslinking system, as this crosslinking is 
performed in the dried state preventing the blocks from separating and aggregating like 
they would when placed in water. This could be a reason the vapor phase 
glutaraldehyde and thiol crosslinking lead to constructs with stiffer properties. 
The other parameter that could explain the difference in the mechanical 
properties is the hydration level, which can greatly affect the mechanical properties of 
elastin[146]. Researchers have shown that the hydration of the hydrophobic residues of 
these materials significantly contribute to the elasticicty of the material[147]. We have 
previously seen that protein based materials that have decreased water uptake have 
greater material rigidity and tensile strength. While our previous work focused on 
changing the hydrophobicity of the protein sequence to achieve this result, we were 
able to produce it based on crosslinker type and method thereof[87]. Interestingly, the 
solution phase glutaraldehyde appears to be a more rigid material than the control even 
when given equal water content.  
In order for comparison between the different materials, a modulus was 
calculated for the linear portion of the plot before and after the yield point. The materials 
with the highest modulus on the first region of the plot also corresponded to have the 
highest modulus in the second part of the plot. The control shows that there is no 
significant difference between the control confined and unconfined samples ensuring 
that the film was not mechanically altered during the process. In the solution phase 
crosslinking subset, the glutaraldehyde produced a stiffer material. It has previously 
been reported that collagen cross-linked by disulfide bridges can attain mechanical 
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properties equivalent to GTA crosslinked collagen[148]. Our mechanical tests also 
showed a strong correlation between the vapor phase glutaraldehyde and the vapor 
phase thiol crosslinking.  
The results of the mechanical tests demonstrated the potential to modulate the 
mechanical properties of the materials by crosslinking them with different crosslinking 
agents and setups. Most crosslinkers are solution based and, therefore, the ability to 
increase the mechanical rigidity of a film by confining it during the crosslinking setup 
was a significant finding. In the field of crosslinkers, most are soluble which in our case, 
lead to less rigid films due to the hydration of the film before the crosslinking could 
occur.  
Degree of Crosslinking 
 The degree of crosslinking for glutaraldehyde and genipin have been 
documented in many reports[139, 149]. However, none of these groups have attempted 
to crosslink materials in a confined setup. Therefore, it was unknown to what degree of 
crosslinking was achievable with the crosslinking systems we were using.  Our working 
hypothesis was that we could minimize the swelling of the film through confinement. 
The confinement would also let the solution phase crosslinker migrate into and out of 
the material through diffusion. However, initial attempts to confine the crosslinking failed 
to produce complete uniform crosslinked films. This was most evident in the genipin 
crosslinked systems, as genipin crosslinking is a colorimetic process in which the 
protein turns blue. It was evident that the initial crosslinking strategy of confining the 
protein based material between two glass slides would not allow for the diffusion of 
crosslinking solution into and out of the material. This resulted in a crosslinking gradient 
115 

where the first few hundred microns were deep blue transitioning to a gradient of light 
blue protein transitioning into uncrosslinked material. To overcome this limitation, the 
protein sheets were sandwiched between filter paper in the constrained setup. The 
schematic for this final design is depicted in Figure 4.1. The filter paper allowed for the 
crosslinking to be present at the top and bottom of the film and decrease the path 
necessary for diffusion. Once this setup was used, films turned a deep blue and, as 
noted in Table 4.2, the degree of crosslinking was close to that of the unconfined 
solution phase crosslinking system. 
Thiol vapor phase crosslinked samples had the highest percent extractables of 
all crosslinked subsets. We believe this is related to the limited mobility of the polymer 
chains in the dried state. Glutaraldehyde, even in the vapor form where chain mobility 
can be considered to be the least mobile had the highest degree of crosslinking which 
seemed counterintuitive. We surmised it is related to glutaraldehyde’s capacity of 
polymerizing crosslinks, thereby allowing it to bridge larger gaps then the other 
crosslinkers. Amongst the glutaraldehyde crosslinking strategies, the vapor phase 
crosslinker had the highest percent extractables, possibly related to the lack of 
movement of the chains in the dried state.  
The percent extractables were also higher in the confined cases than the 
unconfined cases which agrees with the previous thought that less fluid equates to less 
chain movement. However, this is also counterintuitive because as the swelling 
increases it could potentially increase the distance between crosslinking sites. There 
seems to be a question of chain movement and distance caused by swelling.  
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 To determine the crosslinking density, the number of crosslinked groups was 
determined by subtracting the chemically determined number of groups available before 
crosslinking and those determined to exist after, via the crosslinking assay. The most 
accurate way to perform these experiments was in polymer solutions, however, for our 
studies it was not feasible to solubilize the films. Therefore, we performed these assays 
on films and the results allowed for comparative analysis between crosslinker type and 
condition. It should also be noted that the controls showed very little crosslinking and 
therefore the crosslinking groups seemed to be fairly accessible. 
 Lysine residues were initially added to the elastin mimetic backbone to aid in 
crosslinking[87]. Therefore, the ability to crosslink our films by chemically modifying an 
existing residue rather than recreating an entire recombinant insert allowed us to 
manipulate the physical properties of the material. The addition of thiols to collagen has 
been demonstrated previously[150]. The thiol crosslinking strategy showed a degree of 
crosslinking on par with the solution phase chemical crosslinkers. This was an important 
finding as the lysine residues capable of crosslinking numbered eight and the number of 
thiol sites was measured to be between 17 and 18 for a given repeat. The 17 or 18 
comes from the degree of modification; our modification scheme resulted in 64±3.5% 
modification of the film. Therefore, if we could increase the efficiency of the modification 
we could even have a more crosslinked system. As this crosslinking method does not 
use an exogenous compound that allows for bridging to occur between the two 
crosslinking sites a lower crosslinking density and higher percent extractables can be 
expected. Once the H2O2 was added, the chains had an added mobility and the 
oxidation reaction was more favorable from both a kinetics and chemical view point. 
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This was shown in both the low percent extractability number and the high degree of 
crosslinking. Also of interesting note was the ability to subsequently increase the degree 
of crosslinking with a very mild H2O2 solution.  
Discussion in Vitro Drug Release 
The ability to monitor and tailor the drug delivery kinetics was crucial to optimize 
drug choice, drug concentration, and incorporation strategy. In order to quantify the 
delivery kinetics from our test system, we utilized UV spectroscopy because it has high 
throughput and cost effectiveness compared to HPLC. The ability to monitor the drug 
release from part of the stent allowed for the testing of more samples while conserving 
valuable elastin mimetic material and drug. Researchers have shown that planar films of 
the same thickness as stent coatings provided the same release profile for drugs. They 
also showed the ability to extend the duration of delivery by changing the bioabsorbable 
material and drug combination[80]. The drug dose used was based on the BX Velocity 
from Cordis which is a sirolimus-eluting stent that contains 140 µg of sirolimus per 
square centimeter of stent-surface area within a copolymer matrix that was 5 to 10 µm 
thick and was designed to release approximately 80 percent of the total dose of 
sirolimus in 30 days [5]. A study of a bioabsorbable everolimus-eluting stent had a dose 
of 98µg for 12mm stent and 153µg for the 18mm stent[151]. In our system, we used a 
drug dose of 1.4 µg/mm2 of construct.  
 The construct was placed in a release medium because of the low solubility of 
rapamycin in PBS. The solubility of rapamycin in water is 2.6µg/ml and  90mg/ml in 
ethanol[152]. The release medium ensured there were no boundary conditions that 
would lead to a slower release profile than expected. We also showed that the release 
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medium did not affect the physical properties of the construct. However, there was no 
doubt that the dissolution time of the drug and the ultimate diffusion could be greatly 
enhanced by the sink conditions that the release medium created. In the body, the 
diffusion of the drug to the lumen of the vessel could be limited by solubility of the drug 
in the tissue, as has been shown in studies that examined the process of accumulation, 
duration, and distribution of the drug in luminal wall[70, 153].  
Determining the proper drug elution profile was complicated by the delicate 
balance between adequate drug dosage over time and minimal local toxicity. The 
biggest unknown in the drug eluting stent literature is the range for acceptable drug 
release profiles. Drug elution exists to combat the smooth muscle cell overproliferation 
that occurs after stent expansion. An argument can be made that the drug elution only 
needs to occur during this period of overproliferation.  Edelman et al. proposed the most 
referenced model for vascular healing after stenting, and this model shows smooth 
muscle cell proliferation escalates until day 10 [154]. Since there was no consensus as 
to an ideal system, we referenced the literature on existing stent platforms. These 
references showed release systems that had two unfavorable conditions. First, the bulk 
of the antirestenotic agent remain entrapped in the drug eluting coating, and there was 
limited sustained release. In the case of the TAXUS stent, the slow and moderate 
release showed a burst but no sustained release. The fast release had a large burst and 
then a slowed sustained release at a very low drug concentration [155]. The goal of our 
research was to be able to incorporate the drug into the stent matrix and get an initial 
burst, sustained release, and total release of the drug from the matrix.  
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Since the constructs were made from serial castings of elastin mimetic several 
strategies to incorporate drugs exist. The first incorporation strategy employed utilized a 
top coat similar to the commercial stent platforms. Since serial castings do not solubilize 
the previous layer, we were able to perform serial castings of different layers. For the 
top coat strategy, we deposited two layers of elastin mimetic solution without drug and 
then a final third layer of elastin mimetic with drug incorporated. The drug elution 
profiles from these constructs were rapid and included a big burst as seen in Table 4.4. 
The second strategy looked at incorporating drug throughout the matrix, which is 
common in the bioabsorbable stent literature. The second strategy had the most dilute 
drug concentration and drug diffusion was able to occur at both surfaces at time zero. 
This system did not have as large a burst as the top coat strategy. However, the drug 
diffusion was still rapid, and the drug was exhausted between day six and seven. The 
third strategy explored the potential of placing the drug in the middle cast layer. We 
believed that concentrating the drug in the middle of the construct would allow us to 
increase the drug concentration leading to a longer dissolution time and ultimately a 
longer elution time from the construct. Incorporating the drug in the middle layer did 
allow for a decreased burst and a slower release profile. The goal of this strategy was to 
increase the path length that the drug must travel and increase the dissolution time. 
 It was hypothesized that the addition of a crosslinker could alter the drug elution 
profiles. The first issue examined was the potential for drug elution into the crosslinking 
solutions. The drug retention was calculated using Equation 6. As documented 
previously, the solubility of the rapamycin in PBS is very low. As such we believe this is 
why the drug did not elute into the crosslinking solution. The drug release into the 
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crosslinking solution was examined by testing the crosslinking solution for drug release. 
Also the sample constructs were solubilized in TFE and the drug concentration was 
noted. The drug retention rate of the stents was 98.21±1.34%.   
 The ability to modulate the drug release occured on several fronts. First, the films 
had decreased swelling ratios which were proportional to drug released because higher 
swelling ratios aid in solubility and diffusion of the drug. Secondly, the crosslinks 
provided a higher degree of tortuosity, thereby increasing the elution time of the drug 
from the material. Researchers have shown that the drug diffusion coefficient through 
hydrogels decreases as the cross-linking density increases and as the equilibrium 
degree of swelling decreases[156]. 
  Crosslinking has been shown throughout the literature to increase the effective 
diffusivity of the constructs [157]. Glutaradehyde has been known to substantially 
change the microstructure of gelatin constructs which in turn altered the rate and extent 
of drug released from such implants[158]. The higher the crosslinking density, the larger 
effect it can have on the microsturcture, thereby modulating the drug release[159]. This 
was observed in our system as well.  The crosslinks have the ability to decrease the 
porosity of the films[160]. As shown in the physical parameters section, some of the 
crosslinking strategies were able to increase the volume fraction of the protein as well 
as decrease the solution inside the construct. Both of these should increase the drug 
elution profiles from the construct as they decrease the space available between 
macromolecular chains[161].  
Since our current system is diffusion controlled, the ability to extend the retention 
time of the drug further would be very challenging because of the hydrated structure of 
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the matrix. We have shown that placing the drug in discreet sections and crosslinking 
can influence both the initial burst and the release times. In the future work section of 
Chapter 6, we discuss ways to delay the dissolution time of the drug and slow the 
diffusion of the drug from the construct. 
Discussion Cell Studies 
It has been noted in previous studies carried out in our lab that the elastin 
mimetic material is not ideal for rapid endothelialization. Therefore previous 
investigations have lead to the incorporation of cell binding motifs into the protein 
backbone and the incorporation of Fn. The concentration of Fn allowed for adhesion to 
these constructs and enabled us to achieve the desired endpoint. However, it should be 
noted that increasing the Fn concentration should allow for increased adhesion rates in 
the two hour study.  
 There are several potential ways to incorporate Fn onto these biomaterials. 
Mixing the Fn in the material was not practical as the Fn would be throughout the stent, 
ultimately wasting Fn and providing Fn to the smooth muscle cells. The Fn 
concentration on the surface would be relatively low as well. Therefore, we adsorbed Fn 
onto the surface to avoid the detriments of mixing. The adsorption of FN on the surface 
can be performed either before or after the crosslinking step. Initially we thought 
incorporating the Fn onto the surface before crosslinking would enhance the long-term 
availability of Fn on the surface of the materials. However, we found that adsorbing the 
Fn onto the matrix before crosslinking did not yield beneficial results. It was 
hypothesized that the strenuous washing process used to ensure all crosslinker was 
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removed also washed out the Fn. For our application, the most feasible economical 
choice parameters to incorporate Fn onto the surface of the stent was explored. 
The most unexpected result from the cell studies was the lower adhesion and 
proliferation characteristics of non crosslinked elastin mimetic films with Fn. Before 
performing the experiments, these films were expected to perform equal to or better 
then the crosslinked groups. However, throughout all of the tests these films had lower 
cell adhesion numbers than the other materials. A plausible explanation is the Fn 
adsorbs at a different concentration or conformation compared to the other three 
surfaces. In previous work completed by our group[162],a couple of trends were noted 
that seem to exist in these materials. The first is that cells preferred 10% elastin mimetic 
compared to 6%. Therefore, there is a possibility that denser gels allow for enhanced Fn 
adsorption. The other trend is that cells adhered at higher rates on crosslinked materials 
compared to noncrosslinked materials, and it was attributed to the crosslinked materials’ 
ability to retain the Fn[162]. However, it has been shown in the literature that the 
stiffness of the materials the cells are grown on can greatly affect their behavior[163].  
Amongst the crosslinked materials, genipin and thiol had very good adhesions 
rates while glutaraldehyde significantly trailed these two, which fits with the current 
literature in this area. Xi –xun et al. showed HUVEC cell number over a 1, 3, 5 , 7, and 9 
day time course increased on the control and on genipin; however, the constructs 
crosslinked with glutaraldehyde showed a decrease in cell proliferation[164]. Sung et al. 
showed cell viability was decreased in porcine pericardium crosslinked with 
glutaraldehyde  compared to genipin[165]. The ability of cells to adhere to collagen 
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crosslinked with a variety crosslinkers was markedly different and







 The ability to tailor the physical, mechanical, drug delivery, and endothelialization 
properties while achieving favorable biocompatibility was achieved. The ability to 
minimize the physical parameters of thickness ratio, swelling ratio, and water content 
allowed for the creation of thinner struts and also helped achieve favorable mechanical 
and drug delivery properties. The ability to modulate the mechanical properties allowed 
for the use of biocompatible crosslinkers capable of producing acceptable mechanical 
properties. The drug delivery release kinetics were able to be slowed by changing the 
crosslinking conditions and setup. The successful endothelialization of the crosslinked 
constructs was also demonstrated. Finally, this work also showed the ability of using 
thiol based crosslinking to act as another method to crosslink elastin mimetic materials. 
The ability to confine the crosslinking process showed that the properties can be shifted 





In Vitro and In Vivo Stent Deployment 
5.1. Introduction 
The development of a protein based stent provides the framework for a method 
to overcome the limitations of existing stent platforms. In the previous three chapters, 
we have reported the ability to design, fabricate, test, and tailor protein based stents. To 
our knowledge, this is the first time that the development of a purely protein based stent 
has been explored, much less reduced to practice. However, the system still needed in 
vitro testing to ensure proper delivery. We also wanted to explore the feasibility of 
incorporating radiopaque markers, antirestenotic drugs, and cell binding motifs into the 
stent structure. Once this was accomplished, the work shifted to the in vivo model. The 
testing that was done in the preceding chapters validated the potential to crimp, tract, 
and expand the elastin based stent platform. However, these tests did not prove that the 
stent platform could be delivered and deployed in an animal vessel. Therefore, we 
needed to prove that this system was capable of being used as it was designed. 
 In vivo models for stenting often focus on the rabbit iliac and porcine coronary 
models[167]. Compared to these, the rat model has been shown to be simple, 
inexpensive, rapid, and accurate[168]. Researchers have also documented similar 
vascular responses in the rat aorta model with more benchmarked models, such as the 
porcine and rabbit models[169]. There are strengths and limitations with all of the 
animal models discussed above, and in view of the cost and surgical time required for 
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large animal models, the rat aorta model provided a cost effective and simplified model 
for a first round of stent testing.  
 In order to facilitate the deployment of the elastin mimetic stents in the animal 
model, a delivery system was developed. The delivery system consisted of two major 
components: a balloon catheter and a sheath. Novel balloon catheters have been 
developed in other novel stent platforms to allow for proper stent deployment[89]. In this 
specific case, we needed to develop our own catheter to minimize the radial profile of 
the crimped stent system. Sheaths have been commonly used in the development of 
shape memory stents to prevent premature expansion of the stent. In our case, a 
sheath is needed to prevent the stent from hydrating prematurely.  
The aim of this study was to validate the potential to deliver and deploy a 1.5mm 
stent in vitro. Then the drug delivery and endothelialization potential of an entire stent 
was examined. Upon successful completion of these aims a stent deployment strategy 
for implantation in the rat aorta was performed out. It was hypothesized that the stent 
could be delivered and expanded in a section of the aorta distal to renal arteries and 
analyzed for its success over time and its ability to stimulate vascular wall healing. In 
this chapter, we outline the parameters necessary to create this approach and illustrate 




5.2 Materials and Methods 
Stent Fabrication 
The development and fabrication of the stent used in these studies were detailed 
in Chapter 2. The stent employed in all of these experiments had a length of 7mm, a 
diameter of 1.5 mm, and 1.5mm solid ring structures on the proximal and distal end of 
the stent. The stent was also genipin crosslinked. 
Catheter Fabrication 
The catheters were fabricated by covering a 15mm length of precision 304 
stainless steel tubing, that has an outer diameter of 254µm and an inner diameter of 
176 µm, with silastic tubing (Down Corning Midland, MI), that had an inner diameter of 
305µm and an outer diameter of 635µm. A 5mm section of silastic tubing was also 
attached to the tip of the stainless steel tubing. The balloon was formed by placing a 
30mm section of the balloon material, (Advanced Polymer, Salem, NH) that is 6.35µm 
thick and has an outer diameter of 1.6mm, over the catheter. The balloon was twisted 
and cinched down to the silastic tubing, and the ends are secured with cyanoacrylate. 
The cinched ends of the balloon were covered with heat shrink tubing, with an outside 
diameter of 1.1 mm and thickness of 13µm. The heat shrink tubing was heated with a 
heat gun until it shrunk to a nominal diameter of 650µm. A blunt tip 27 gauge needle 
was inserted into the distal end of the silastic after it had been placed in toluene for 1 
minute to swell the tubing. The toluene was than allowed to evaporate from the silastic 





 The sheath was created from two components. The first was a 1.25mm outer 
diameter sheath that has a thickness of 6.35µm. This sheath was passed over the 
0.96mm sheath that has a thickness of 13µm and they were attached via cyanoacrylate.   
Stent Delivery 
To prepare the catheter for crimping, the balloon was deflated and flattened. The 
stent was then placed over the flattened balloon and the stent was flattened. The stent 
is then manipulated with surgical tweezers to allow for the stent and the balloon to be 
crimped as seen in Figure 5.2C. The stent was then allowed to dry prior to sheath 
placement. The loaded stent catheter system was traveled to the site of deployment. 
The sheath was removed, and the balloon was inflated to 3 atm using an inflator 
(Boston Scientific, Natick, Massachusetts) filled with sterile phosphate buffered saline. 
The inflated balloon was maintained for 1 minute, and then the balloon was deflated and 
withdrawn from the system. 
Determination of Physical Parameters of Delivery System 
  The best practice in stent fabrication is discussed in Chapter 3. For these 
calculations, we used the same techniques that were used to determine stent thickness. 
The pre and post expanded stent thicknesses and diameters were measured by 
examining the proximal and distal ends of the stent. Once an image was taken, the 
stents were measured at eight points every 45º. The stent was always aligned so the 
attachment point was centered on 0º. The wall thickness would be characterized by 
measuring the thickness at all eight points. Crimped profile was determined by 
examining the proximal and distal end of the stent after the crimping process. The 
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crimping ratio was determined by subtracting the initial surface area of the uncrimped 
stent from the crimped stent and then dividing that difference by the uncrimped surface 
area. The void volume of the crimped stents was calculated by subtracting the surface 
area of the stent from the surface area of the crimped structure. The stent was then 
examined along the length and measured using image J. The radius of curvature was 
determined by placing the catheter system with stent on a template with a bending point 
and two movable assists, which were used to bend the stent. The diameter of the 
bending point was decreased until the system started to kink.   
Collapse Pressure Setup 
The same collapse pressure setup as described in Chapter 2 was utilized to 
quantify the collapse pressure of stents before and after the crimping process. 
Video Acquisition Setup 
 The video acquisition system was used to monitor the deployment and expansion 
of the stent, as well as the stent delivery process. 
Radiopaque Marker Incorporation 
Radiopacity in the stent was achieved by adding tantalum to the construct. This 
was accomplished in two ways. The first way was to incorporate the tantalum into the 
mold before the elastin was cast in the mold. A suspension of ethanol and tantalum at a 
concentration of 1 gram/ml was used.  The radiopaque doped elastin mimetic stent was 
then imaged using fluoroscopy.  
 Drug Incorporation 
Drug incorporation was detailed in Chapter 4. In brief, the drug was mixed with 
the polymer solution and solvent cast into molds. 
130 

Experimental Procedure to Implant Stents in Rats 
In the rat procedure, all surgeries were performed using a dissecting microscope 
(VWR™). Once the animal was anesthetized with isoflurane, a vertical midline 
laparotomy incision was made. After appropriate retraction for exposure, the abdominal 
contents were displaced to the left upper quadrant and covered in saline moistened 
sterile gauze. The bladder and seminal vesicles were displaced deep into the pelvis and 
similarly held in place with moistened sterile gauze, allowing for adequate exposure. 
The retroperitoneum was dissected to expose the infrarenal abdominal aorta to the level 
of the aortic bifurcation. The dissection planes between the aorta and the IVC were 
established 3-5 mm below the level of the left renal vein and 3-5 mm above the 
common iliac bifurcation. Each was further delineated by careful dissection along these 
planes. A microvascular clamp was applied to control aortic inflow and outflow at the 
proximal and distal regions just described. A 19-gauge needle, bent at a right angle, 
was used to create an arteriotomy approximately 8-10 mm above the common iliac 
bifurcation. A tie was placed proximally to the arteriotomy. This tie prevented blood from 
coming out of the aorta once the clamp was removed. A 1mm sheathed balloon and 
stent was inserted intraluminally via the arteriotomy. The proximal microvascular clamp 
was removed to allow free passage of the sheathed catheter. The catheter, which had 
been previously marked at various points, was inserted to the level of the bifurcation 
and then drawn back 1 cm. The sheath was then removed and the balloon was inflated 
to 3 atm. The balloon was kept inflated for 1 minute before it was deflated and removed. 
Prior to complete removal of the catheter, the proximal clamp was replaced to regain 
inflow control. The arteriotomy was closed with 9-0 Nylon suture in a running fashion. 
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The proximal and distal micro-clamps were removed to restore anterograde blood flow 
(confirmed by pulsation along the length of the aorta). The abdominal contents were 
replaced with care taken to avoid intestinal torsion, and the abdomen was closed in two 
layers with running 4-0 vicryl suture. 
5.3 Results and Discussion 
In this chapter, we discussed the implementation of the stent platform refined in 
Chapter 2 along with the material modulation we discussed in Chapter 4.  However, first 
we had to design and develop a stent delivery system that was capable of delivering 
and deploying these novel elastin mimetic stents in rat aortas. To achieve this end, 
elastin mimetic stents were fabricated with a 1.5mm diameter, a thickness of 100µm, 
and a length of 7mm. In order to develop, validate, and refine a delivery and deployment 
process capable of in vivo testing, several endpoints had to be achieved that were 
based on the in vivo model chosen, the rat aortic model(Table 5.1). The feasibility and 
reduction to practice of these endpoints was achieved by vetting the stent with a series 
of in vitro tests. In Chapter 2, we explored the design and development of stents that 
allowed us to achieve certain physical features. The current stent design reflects the 
design parameters that had to be satisfied to ensure this stent functions properly. 
However, in so doing we created a stent that cannot be deployed in the rat aorta with 
generic balloons and sheaths. Therefore, we had to develop a balloon catheter system 
to successfully deliver these stents into mock arteries and achieve the endpoints listed 




   Table 5.1 In Vitro Benchmarks  
Development of Catheter System 
Balloon catheters are fairly common devices that have been used for decades to 
deliver and expand stents at the site of stenosis. Before stenting was common practice, 
angioplasty balloons were used to open vessels that were partially blocked with plaque. 
A standard balloon catheter is composed of a balloon, tubing, and leurlocks to connect 
to an inflator. The problem with current commercially available balloon catheters is that 
the dimensions have not been optimized for our stent. The protein based stent’s inability 
to be crimped with the standard processes created a higher cross sectional area, 
creating a radial profile that was too large for the rat aorta. Therefore, based on both our 
stent design and the animal model chosen, a complete redesign of the current balloon 
catheter setup had to be investigated.  
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 The focus of the new catheter design was to maintain the reliability and 
functionality of current balloon catheters while minimizing their void volume and radial 
profile. Limiting the radial profile of the balloon catheters was achieved by replacing the 
plastic components of the catheter with low profile metallic components that achieved 
the same flexibility and trackability of the current catheters. The differences between 
standard balloon catheters and the new catheter system that was developed are 
illustrated in Figure 5.1. Current catheters have a larger diameter plastic tube, on which 
the system is placed. In our catheters, we reduced the diameter of this tubing from 
780µm to 240µm and changed it from plastic to metal. 
Figure 5.1 (A) Standard catheter design, (B) Experimental catheter design, (C) Zoomed in 
portion of B, a denoted balloon, b denotes attach mend point, c is inner lumen, d is outer lumen 
and (D) The distal end of the catheter  
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 Initially the catheter tubing was replaced with concentric stainless steel tubing 
that allowed for a dual lumen and a small profile. However, this system was prone to 
kinking which would prevent the balloon from inflating. Thicker stainless steel that 
prevented kinking proved to lack the flexibility needed for the catheter to perform 
properly. Therefore, we removed the outer stainless steel tubing and replaced it with 
silastic tubing. This setup allowed for flushing the vessel with PBS and inflating the 
balloon, all while maintain the proper trackability of the system.  Figure 5.1B shows 
differences in the radial profile of the existing catheters and the ones we developed. It 
should be noted that the portion of our catheter where the stent resides has a radial 
profile of 230µm, while the radial profile of the commercial catheter is 780µm.  
Balloons were not commercially available at the 1.5mm size we needed. 
Therefore, we ordered thin walled tubing and cinched down the ends to create a 
balloon. The length, wall thickness, and material all affected the performance of the 
balloon. The balloon must be longer than the stent to ensure proper inflation. Initially we 
used a 25mm long balloon; however, when this procedure was transitioned to in vivo 
studies that length was too long so it was truncated down to 15mm. Two balloon 
thicknesses were studied. The first had thickness of 12µm and performed favorably 
upon inflation; however, it was too rigid to allow for proper crimping and deflation.  The 
6µm balloon thickness was more flexible, yet still provided the needed inflation force 
and could easily be crimped down and deflated.  
One of the early limitations of our catheter was maintaining inflation pressures 
4 atm. When the pressure would rise in the system, the PBS would leak from the 
proximal and distal ends of the balloon and from the attachment point of the needle and 
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silastic tubing. To address the leaks from the balloon, the cinched down portions of the 
balloon were covered with heat shrink tubing. The heat shrink tubing created a better 
seal and reinforced the attachment point of the balloon to the catheter allowing us to 
achieve higher pressures in the balloon. A 27 gauge blunt needle was inserted into the 
distal end of the silastic tubing. The 27 gauge needle was larger than the lumen of the 
silastic tubing so the silastic tubing was placed into toluene which swelled the tubing 
and allowed for the insertion of the needle. Upon evaporation of the toluene, the silastic 
tubing was contracted around the stent. Finally to prevent the tubing from moving on the 
needle, a suture was tied over the tubing needle interface. 
Stent Insertion and Travel 
The insertion of the stent and delivery of it to the site of deployment required a 
minimal radial profile, lubricious surface, prevention of stent migration, and sheath 
removal. A minimal radial profile was able to be achieved with the proper crimping 
strategy. The radial profile was minimized by selecting sheaths with small diameters 
and thicknesses in an effort to prevent damage to the vessel and to minimize the shear 
on the delivery device as it is traveled in the vessel. To aid in insertion, the tip of the 
sheath was crimped to be slightly tapered at the tip further decreasing the radial profile. 
The sheath was used to prevent the system from hydrating, which would increase the 
system radial profile. As previously demonstrated, the elastin mimetic stents can 
hydrate and begin to swell on very short time scales. The sheath also fixed the radial 
profile, which was important for insertion. On the unsheathed stents, the stent was 
getting stuck at the insertion point effectively increasing the stent diameter.  
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The sheath also prevented stent migration as the sheath created a uniform 
circumferential diameter that was subjected to the shear stress created during insertion. 
Preventing stent migration is important because stent migration off the back of the 
balloon would prevent expansion, but the stent should be able to be withdrawn on the 
catheter. If the stent migrated, off the front end of the balloon the stent would become 
separated from the catheter and retrieval could pose a life threatening condition. 
Sheath Removal 
 As noted above, without the sheath, delivery of the elastin mimetic stent would 
be almost impossible. However, the sheath must be able to be removed to allow it to 
function properly. There were three places where sheath removal lead to problems. The 
first was the ability to uncrimp the sheath and retract it over the stent and balloon. The 
second was the interface between the sheath and the silastic tubing. The third was the 
ability to remove the sheath if the stent started to hydrate.  
These first two limitations were overcome by changing the thicknesses of the 
sheath. When 6µm sheaths were used, their flexibility allowed the catheter to open the 
proximal twisted end and expel the stented catheter without moving the stent on the 
catheter. The next problem overcome by changing the thickness of the sheath was the 
interface between the silastic tubing and the sheath. The thin sheaths, 6µm, were flimsy 
and crumpled on the silastic tubing, preventing the sheath from being able to be pulled 
back. When the distal portion of the sheath was replaced with a 12µm thick section, the 
sheath was allowed to move freely on the catheter.   
It should also be noted that even with the tip of the sheath crimped, stent 
hydration problems still plagued the delivery of the stent. With the small tubing, capillary 
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forces sucked in a large amount of the PBS that was in the mock vessel, causing the 
stent to swell and get stuck in the sheath. In previous studies with patterned stents, this 
was not a problem as the sheaths were not as tight as the current sheaths needed for 
rat aorta model. The crimped tip prevents the hydration as noted previously; however, 
once the sheath started to be removed, the solution rushed into the sheath. Even at 
shorter time scales, the stent swelled enough to cause the stent to get stuck in the 
940µm sheath. This premature hydration led to a large amount of stress on the stent 
which ultimately lead to the failure of the stents in the in vitro system and was further 
exacerbated in the in vivo studies. To overcome this problem, a larger sheath was used 
that has a inner diameter of 1.25mm and a thickness of 6µm. Since the stent was still 
crimped down to a diameter of 900µm, the stent had plenty of room, and the sheath was 
compliant enough to allow for insertion and delivery. 
In Vitro Testing and Design Revisions  
In order to test the utility of the stent and delivery system in vivo, several test 
parameters had to be cleared in vitro. The in vitro system we developed used thin 
walled tubing that served as a mock artery as well as PBS flow that served as the fluid 
in the system. The mock vessel was clear to allow us to visualize the delivery and 
deployment of the stent as well as the expansion, deflation and removal of the balloon, 
and mechanical testing.  
Stent Crimping, Delivery, and Deployment 
To ensure that the catheters we developed in house were able to be crimped 
with the methodology explored in Chapter 2, we revisited the crimping of the stent. In all 
of these cases the crimping of the stent took place on the balloon, and the stent was 
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pleated with surgical tweezers. Crimping the stent on the balloon eliminated the wasted 
spaced that was formed when the two entities were crimped in progression and allowed 
for more uniform expansion of the stent.   
Figure 5.2 (A and B) Uncrimped Stent (C and D) Crimped Stent 
Once the stent was traveled to the deployment site the sheath was removed. 
The sheath was retracted 25mm, to ensure the sheath is completely clear of the balloon 
there are markings on the sheath and catheter that must be aligned. The balloon was 
then inflated with PBS to 3atm with an inflator. To prevent some of the initial elastic 
recoil, the balloon was kept inflated for 1 minute after stent expansion allowing any 
stresses built up in the stent during the crimping and expansion process to relax.  
The catheter has been tested to ensure that the balloon would inflate and deflate 
properly. We monitored the deflation of the balloon to ensure that it did not affect the 
diameter of the stent. Once the balloon was deflated, it was withdrawn from the vessel, 
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and it was noted that the thicker balloons, 10µm, affected both the ability to deflate the 
balloon and withdraw the balloon without moving the stent. 
Ensure Proper Deployment 
Once the stent was expanded it was examined to determine proper stent 
deployment, including uniform expansion and radial profile. The mechanical properties 
of the stent were then tested to ensure the delivery process did not affect the 
mechanical properties of the stent. Stent recoil was monitored at both short and long 
time points, and there was no change in size. To ensure there was no recoil stents were 
expanded in PBS, and their inner diameters was measured over time. 
Expansion
For the elastin mimetic stent to be successful, it needs to have reliable uniform 
expansion so clinicians can size appropriately. Also, from a mechanical standpoint, the 
expansion of the stent was critical as defects in the expansion will compromise the 
mechanical integrity of the stent and create weak points that could lead to collapse. 
Failure to achieve predicted final stent diameter is a common problem, related to 
balloon under expansion and stent recoil, with commercial stents. In fact, the final stent 
minimal lumen diameter is only 73% of the expected diameter, irrespective of vessel 
size[170]. In order for the balloon expansion to perform optimally, three things are 
required: proper stent placement, uncompromised balloons, and proper catheter 
function. 
To ensure proper expansion, we examined the balloon and the stent and 
ensured that the stent did not migrate off the balloon. Stents that did migrate had poor 
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expansion because part of the stent was not expanded by the balloon. Stent migration 
on the balloon was eliminated by addressing the sheathing issues discussed above in 
the sheath design section. It was also aided by the crimping process’s ability to 
intertwine the stent with the balloon.   
The other problem that we noted was a failure for the balloon to expand. This 
was a result of the crimping process. If the balloon was punctured during the crimping 
process, it did not inflate properly. This limitation of stent expansion was corrected by 
taking more precautions during the crimping process. The early catheter designs led to 
shaft crimping, which prevented the PBS from inflating the stent. When the outer lumen 
was changed from stainless steel to silastic tubing, this limitation was mostly overcome.  
Stent Recoil 
A study of the standard recoil for several metallic stents showed a standard stent 
recoil between 2.18% and 6.40%[171]. However, fabricating the stent in the expanded 
form allowed us to minimize this limitation as detailed in Chapter 2. Successfully 
deployed stents had recoil of 1.3±0.7%. This lack of recoil follows the hypothesis that 
stents fabricated in the expanded form and then crimped down would experience less 
recoil than stents expanded from a nominal diameter. Once a stent had been expanded 
it was monitored for elastic recoil. As discussed in the design rationale section this 
property was not seen as much in self expanding stents as balloon expandable stents. 
Elastic recoil was seen more in polymeric stents that were fabricated in the crimped 




Since the stent was crimped by folding, the inner profile of the stent was 
examined to ensure the lumen was still round and not deformed from the crimping. One 
of the concerns was the pleating and folding of these stents would impart some 
irrecoverable deformation that would cause the stent to lose round when deployed. We 
investigated this at both short-term and long-term time points, 1hour and 1 week. There 
was some deformation that occurred as the stent does not recover its entire shape after 
hydration, however, the stent does recover most of its initial shape. The fact that we 
dried the stent could aid in the process as the mechanical creep that the stent would 
experience is lessened because the polymeric chains lack flexibility in the dried state.   
Mechanical Properties 
Detailed mechanical testing on different stent designs and stent processing 
methods were discussed in detail in the stent design sections. However, to ensure that 
mechanical integrity of the stents was not compromised, through the crimping, delivery, 
storage, and expansion process, collapse pressure tests were performed. Stents were 
fabricated, hydrated, crimped down, dried, sheathed, stored for 1 week, tracked to the 
site of expansion, unsheathed, expanded for 1 minute, the balloon was removed and 
the stent was tested. These tests show that the crimping, storage and 
sheathing/unsheating processes do not affect the mechanical integrity of the 
stent(Figure 5.3).  
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Figure 5.3 Collapse Pressure Before and After Stent Loading  
Incorporation of Radiopaque Markers 
Stents are an endovascular device and, as such, require fluoroscopy to allow 
clinicians to visualize the stent and ensure proper delivery and deployment. Radiopacity 
is a material property that obstructs the passage of x-rays, thereby giving objects such 
as metallic stents good contrast in the vessel. Some of the thinner metallic stents and 
self expanding stents fabricated from nitinol have had limited radiopacity, which limited 
their utility. To overcome this property, gold or tantalum markers were added to their the 
proximal and distal ends[172]. Imparting radiopacity into the elastin mimetic stent was 
crucial to allow for their endovascular deployment. The radiopacity of the elastin mimetic 
stent was also increased with the addition of tantalum microparticles.  
Microparticles allowed for easy incorporation of the tantalum into the elastin 
mimetic stent through several different processing steps. The easiest way to incorporate 
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the tantalum material was to suspend the tantalum in TFE and syringe the solution into 
the proximal and distal ring reservoirs in the stent mold. Once the TFE evaporated, the 
tantalum was left in the mold and elastin mimetic solutions were cast into the mold. It 
should be noted that the tantalum was confined to the ring sutures to allow for 
determination of the proximal and distal ends of the stent, as well as for prevention of 
tantalum incorporation into a section that has to be ablated with the excimer laser.  
Microparticles were also selected for their potential for being excreted from the 
body. Since the elastin mimetic stent can ultimately be degraded and absorbed back 
into the body, tantalum microparticles were selected instead of larger radiopaque 
markers. The particle size of the tantalum allows for it to be excreted by the body and 
not clog the vasculature.  
Figure 5.4A shows different quantities of tantalum in the ring components of the 
stent design. The weight of tantalum ranged from 10µg, 25µg, 50µg, 75µg, and 100µg. 
Figure 5.4B shows the stents under fluoroscopy with a 3mm nitinol stent and a 6mm 
stainless stent.  Finally Figure 5.4C shows the stent on a commercially available 
delivery catheter. There are three radiopaque markers on the sheath and one on the tip 
of the catheter. The sheath was then pulled back to reveal the proximal half of the stent 
and demonstrate the appearance of an unsheathed stent.  
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Figure 5.4  (A) Stent rings with different concentrations of tantalum(B) Stent rings examine 
through fluoroscopy with commercial stents above and below (C) Elastin mimetic stent doped 
with tantalum inside the delivery catheter (D) Stent half way out of the delivery catheter. 
Pharmaceutical Incorporation 
Drug eluting stents have shown to be effective at combating restenosis. To this 
end, we explored the ability to deliver drugs from the elastin mimetic stent platform. In 
these studies, rapamycin was used as a model drug because of its long documented 
history as an anti-restenotic drug incorporated into commercial stent platforms, such as 
the Cordis Cypher. The concentration of sirolimus on the surface of the Cordis Velocity 
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stent is 140 µg/cm2[5]. This is the range that has been reported in the literature for other 
drug eluting stents, both coated metal and bioabsorbable stents, and will allow us to 
compare the elution rates of commercial stents and the elastin mimetic stent. The 
stent’s drug delivery potential was studied in a release medium to allow for the 
generation of sink conditions. It should be noted that that in a PBS based system the 
drug would remain sequestered in the stent because of the low solubility of the drug in 
PBS[152]. 
In the first study, drug was incorporated throughout the stent, and differences 
between crosslinked and noncrosslinked stents were explored. We have previously 
demonstrated the potential for crosslinking to affect drug release(Chapter 4). Those 
results also held true in these full stent studies. Compared to the uncrosslinked stent, 
the crosslinked stent had a lower burst and a slower release rate coupled with extended 
release duration (Figure 5.5A). The burst release of the uncrosslinked stent was 
significantly higher than the crosslinked stent. Table 5.2 also shows that the duration 
that the drug remains in the stent was significantly higher for the crosslinked stent over 
the noncrosslinked stents. The crosslinked stent also had a lower burst release and a 
lower drug delivery rate. It should be noted that the crosslinking solution was measured 
to determine if any drug had eluted out of the stent, and no measurable drug elution 
from the stent into the crosslinking solution. 
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Figure 5.5. (A) Illustrates the potential for crosslinking to extend elution profiles. (B) Illustrates 
the elution profile for a crosslinked elastin based stent that has the drug located in discrete 
portions of the stent.  
Table 5.2.Parameters from drug elution studies.  
We then explored the potential of incorporating the drugs into discrete sections of 
the stent, namely the rings or the struts. The release profiles of the stents were dictated 
by the concentration and location of the drug in the stent(Figure 5.5B). The burst 
release of drug from the stent matrix was significantly higher than the ring portions. The 
147 

fact that the burst release increases more than 60% shows the potential to modulate 
drug release by incorporating the drug into discrete areas. 
While it is obvious that the general release profiles for the different locations are 
similar, it should be noted that the initial burst release and the steady release thereafter 
are affected by the placement of the drug in the matrix. The ability to incorporate drugs 
in different portions of the stent appears to be an advantage of the molding fabrication 
process that can be leveraged to achieve longer drug delivery times and alter the burst 
release for the particular drug of interest. When comparing the stent rings and the 
struts, the two main variables are concentration of drug with regard to vessel area that 
the stent interacts with and the geometry. The weight by weight of the material and the 
drug are only slightly different. Therefore, the delayed drug release must be explained 
through the geometry. It should be noted that casting of the stent led to no measurable 
mixing between the two areas. Although the surface area of these two delivery 
platforms was almost identical, the geometry of the drug locations is quite different. In 
the matrix portion, the struts surface to thickness ratio was 5 to 1, whereas the rings 
have a ratio of 15 to 1. Therefore, the matrix could be losing a significant amount of 
drug through the sides perpendicular to the vessel wall. 
All of the drug release profiles had a characteristic burst followed by a linear 
period of higher and then slower release rates as the remaining concentration of drug in 




 One of the biggest drawbacks for drug eluting stents is late stage 
thrombosis[173], which can be overcome if the lumen of the stent can be fully 
endothelialized. The potential to endothelialize recombinant elastin mimetic materials 
has been previously documented [51, 53]. The elastin mimetic material has shown poor 
endothelialization without the addition of cell binding domains either along the protein 
backbone or via the incorporation of Fn[174]. In these studies, we were able to 
demonstrate the ability to obtain endothelialized stent surfaces with Fn passively 
adsorbed to the luminal surface of the stent. From a design point of view, the logical 
placement of biopharmaceuticals would be the luminal side of the stent to try and 
promote cell adhesion. 
 The potential to promote endothelial cell adhesion and proliferation was explored 
by passively adsorbing Fn to the control well and to the genipin crosslinked stent. Once 
the cells were seeded, they were harvested at two hours and a CyQuant assay was 
performed. The control well had an adhesion of 29.8±2.8%, while the stent construct 
had 22.1±3.8%(Figure 5.6A). The results of the CyQuant assays show that the 
adhesion rate for the stent construct was 73.3% when normalized to Fn. The cell 
number at 48 hours was 12487±456 for the control and 9245 ± 579 for the stent 
construct. The control had a 4.93 fold increase from 2 to 48 hours, while the stent had a 
4.61 fold increase. These results show that the HUVECs can adhere and proliferate on 
the stent surface, which provides the framework for an endothelialized stent.  
 The cellularized stent sections were imaged to show the morphology and 
concentration of cells on the surface of the stent construct(Figure 5.6B and C).  It was 
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apparent that 2 hours after seeding, cells are spreading and only a small fraction of the 
stent was cellularized(Figure 5.6B). After 48 hours, the HUVECs are forming a confluent 
layer; however, there are some sections that are bare and this could be a result of the 
nonuniform adhering of the cells after the cell seeding step(Figure 5.6C). The ability to 
seed stent constructs shows that these materials are capable of modification, and this 
modification was much easier than the incorporation of cell binding motifs into the 
protein backbone, as has been accomplished by our lab[162] and others[48, 175].  
Figure 5.6. (A) Cell adhesion and proliferation on Fn polystyrene and Fn on stent section. (B) 
Genipin crosslinked stent after 2 and (C)48 hours post seeding.   
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In Vivo Model  
Deploying the elastin mimetic stent in an animal model was the next logical step 
after the system was vetted with in vivo tests. In vivo models for stenting often focus on 
the rabbit iliac and porcine coronary models. However, the rat model has shown 
increasing promise over the past couple of years because of it low cost and high 
throughput[168, 176-182]. Researchers have also documented similar vascular 
responses in the rat aorta model to more benchmarked models such as the porcine and 
rabbit models[168, 169, 183]. Of importance to our drug delivery studies was the ability 
of the rat model to demonstrate reliable and reproducible in stent restenosis formation 
following stenting of the rat aorta[184]. It should also be noted that a couple of groups 
have explored novel drug delivery studies using the rat model [179, 185].  
We were successfully able to deploy a 1.5mm stent which was in the range of 
stents previously deployed in this vessel[178]. The elastin mimetic stents were 
implanted in the aorta below the renals of the rat(Figure 5.7) following the standard 
procedure established previously. The experimental protocols were approved and 
performed in compliance with the proper review boards.
 The rat aorta model allowed us to perform initial studies on implanting the stents 
in an animal test bed. The ability to use a model where the entire process can be 
visualized allowed us to see potential problems with the delivery system and stent 
deployment and work to eliminate them. We were able to implant stents in eight rats 
and had a 100% survival rate at two weeks. This was very promising as the literature 
has a referenced a much higher mortality rate than we experienced. Inserting and 
deploying the stent through the aorta lead to a mortality rate of 57% for Oyamada et al. 
151 

[186]. They had a lower mortality rate, 11% when the stent was inserted through the 
iliac and expanded in the aorta, but still high compared to our enrollment. Onuta et al. 
had a mortality rate of 17%[181]. 
Figure 5.7 Diagram of rat circulatory system (http://www.biologycorner.com) (B) Site of 
Deployment (C) exposed ligated aorta, and (D) catheter loaded into the aorta 
We were able to demonstrate stent deployment in the rat aorta(Figure 5.8). The 
animals were sacrificed at two weeks and at that time there was no signs of stent 
failure, which was usually reported in the literature as hind leg ischemia. While there is 
much more work that needs to be done, this is a significant step in translating the 
protein based stent from a design to a feasible device. 
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Figure 5.8 Elastin mimetic stent deployed in the rat aorta distal to renals.  
5.4 Conclusions 
 The completed in vitro experiments were able to produce a delivery system that 
eliminated many of the failure points that would have been experienced in vivo. We 
were also able to demonstrate the potential to modulate drug delivery form the stent 
platform and endothelialization of stent constructs. The potential to use these protein 
based stents has several advantages over current platforms, and the delivery and 
expansion of these stents in an animal model provides the framework to study these 
stents further. As discussed in the preceding chapters, the chief advantage of these 
stents resides in the ability to modulate various mechanical and biological properties 
ranging from stiffness to endothelialization. The elastin mimetic stent has emerged as 





Conclusions and Future Directions
Cardiovascular stenting as a means to open occluded vessels will be a 
necessary treatment for the foreseeable future. However, it will be necessary for the 
stents to be able to overcome the deleterious side effects that have plagued stenting 
over the past decade. To exploit the full clinical potential of stents they will need to be 
able to be tuned to specific lesion and patient characteristics. These can be achieved by 
incorporating pharmaceutical and bio pharmaceuticals to enhance stent performance. 
Also the potential for stents to perform their task and then adsorb back into the body 
provides a way forward that eliminates some of the chronic concerns of stenting.  
The work encompassed in this thesis provides the foundation for the long-term 
goal of designing a protein based stent platform. A great number of endpoints have 
been achieved, however, several recommendations for future investigators have been 
proposed for each research chapter.  
Chapter 2 Stent Design and Development: The current stent design that we 
selected has shown promising mechanical attributes. However, future designs should 
look at minimizing the overall ring length and potentially incorporating several thinner 
rings throughout the construct. The ratcheting stent ideal should also be explored in 
further detail to see if the mechanism can be worked out. This kind of design would 
save a great deal of time and energy in crimping down the stent to an acceptable radial 
profile as well as prevent the need to attach planar sheets.  
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 The crimping process must also be enhanced to prevent the laborious task of 
crimping the stent and the potential for nonuniformities that arise when something is 
performed manually.  
Chapter 3 Fabrication of Protein Based Materials: As the knowledge on 
protein based materials continues to expand and the barriers to produce these material 
lessen I believe there will be further implementation of these materials into medical 
devices. When these materials are adopted by the medical device community there will 
be a demand to fabricate these materials into a wide range of constructs. 
The ability to machine protein based materials with the excimer laser has been 
known for a couple of decades in the medical field, however, it has been slow to be 
adopted by the research field. In fact no publications could be found that fabricated 
three dimensional mechanically robust patterned films. The ability to fabricate these 
films allow for more translation into the medical device space. This technique is already 
being looked into by collaborators to pattern biomaterials for tissue engineered blood 
vessels and brain tissue for nerve cell engineering. I believe that this technique on 
protein fabrication will be explored further and refined.  
Finally, we have shown the potential to fabricate thin walled tubes. However, we 
have not had the capacity to laser ablate the fenestrations directly on these thin walled 
tubes. This creates a lot of problem with attaching the stent as shown in Chapter 3. 
Therefore, I believe that a top priority for stent fabrication should be acquiring the 
potential to fabricate stent form thin walled tubing.  
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 Chapter 4 Advancing the Biological and Physical Properties of the Elastin 
Mimetic Material: One of the biggest driving forces in the use of recombinant protein 
engineering is the ability to tailor the proteins to a specific need. However, this process 
is time intensive and not always possible. Therefore, the ability to reengineer existing 
protein sequences with exogenous materials decrease the research and development 
time and cost to obtain enhanced materials.  
 We have explored three crosslinkers and three crosslinking systems. The ability 
for these systems to modulate the properties of the film will be further explored with 
other crosslinking agents. The ability to create more crosslinking sites on the protein 
backbone will also be utilized as a way to enhance crosslinking or as a handle to bind 
other compounds of interest.  
 While we were able to modulate the drug release from our films the time scales 
were not adequate for most applications. Therefore, other methods to retard drug 
elution should be explored. The easiest way to increase diffusion time would be the 
incorporation of drug loaded films or microspheres. The second aim would be to 
increase the dissolution time of the drug. This could be accomplished by crystallizing 
the drug or creating predefined drug reservoirs on the stent where the drug is heavily 
concentrated. The final aspect of delivery would be to release drugs based on 
degradation. This is seen in the bioabsorable stent literature where a top coat can 
dissolve releasing the drug as it degrades. 
 The ability to endothelialize the constructs should also be explored in greater 
detail. It was noted in our research that the Fn would wash out if it was adsorbed prior to 
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construct crosslinking. Further work needs to be done to ensure we can maintain Fn on 
the surface for several weeks. Also other cell binding sequences that are specific for 
endothelial cells or antibodies capable of binding CD34+ cells should be incorporated 
into the lumen of the stent. 
Chapter 5 In Vitro and In Vivo Stent Deployment: The deployment of elastin 
mimetic stents into the rat aorta was a huge milestone for us to achieve. However, that 
is only the beginning of studies that need to be explored to examine the different 
properties of the stent. Future, stent studies will be explored to further determine the 
potential for the elastin mimetic stents to prevent thrombosis formation, combat 
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